var title_f10_8_10368="Central line PI";
var content_f10_8_10368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Central line",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows a central line, which is a thin, flexible tube. One end is put into a large vein, usually in the neck. The other end stays outside the body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10368=[""].join("\n");
var outline_f10_8_10368=null;
var title_f10_8_10369="Circumcision restraint PI";
var content_f10_8_10369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Baby restraint for circumcision procedures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10369=[""].join("\n");
var outline_f10_8_10369=null;
var title_f10_8_10370="Sebac cell ca";
var content_f10_8_10370=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sebaceous carcinoma of the eyelid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mimic of blepharitis, but with only unilateral findings. Here the bump on the medial upper lid is concerning due to its vascularity and alteration of both the lid margin architecture and the lash line.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10370=[""].join("\n");
var outline_f10_8_10370=null;
var title_f10_8_10371="Appendicolith on abdominal films";
var content_f10_8_10371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Appendicolith on abdominal films",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain film of the abdomen reveals a 1.2 cm calcific density, an appendicolith. The patient presented with right lower quadrant pain and was diagnosed with acute appendicitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10371=[""].join("\n");
var outline_f10_8_10371=null;
var title_f10_8_10372="Petechiae in immune thrombocytopenia";
var content_f10_8_10372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Petechiae in Immune Thrombocytopenia (ITP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 177px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Petechiae in a man with immune thrombocytopenia (ITP).",
"    <br/>",
"    (A) Dense, cutaneous petechiae on the foot and ankle. There are no petechiae on the sole of his foot, a site at which the vessels are protected by the strong subcutaneous tissue.",
"    <br/>",
"    (B) Occasional petechiae on the patient's face and large, bullous hemorrhages on the buccal mucosa, which are related to the lack of vessel protection by the submucosal tissue. Similar petechiae and hemorrhagic bullae can be seen in patients with thrombocytopenia of any cause.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stein JH, Internal Medicine, 5th ed, Mosby, St. Louis, 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10372=[""].join("\n");
var outline_f10_8_10372=null;
var title_f10_8_10373="Brompheniramine, pseudoephedrine, and dextromethorphan: Patient drug information";
var content_f10_8_10373=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Brompheniramine, pseudoephedrine, and dextromethorphan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3222?source=see_link\">",
"     see \"Brompheniramine, pseudoephedrine, and dextromethorphan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anaplex&reg; DM;",
"     </li>",
"     <li>",
"      Bromaline&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Bromdex D;",
"     </li>",
"     <li>",
"      Bromfed&reg; DM;",
"     </li>",
"     <li>",
"      Bromphenex&trade; DM [OTC];",
"     </li>",
"     <li>",
"      Brotapp-DM;",
"     </li>",
"     <li>",
"      LoHist PSB DM [OTC];",
"     </li>",
"     <li>",
"      Myphetane DX [DSC];",
"     </li>",
"     <li>",
"      Neo DM;",
"     </li>",
"     <li>",
"      PediaHist DM;",
"     </li>",
"     <li>",
"      Q-Tapp Cold &amp; Cough [OTC];",
"     </li>",
"     <li>",
"      Resperal-DM",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to brompheniramine, pseudoephedrine, dextromethorphan, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, a large prostate gland, glaucoma, very bad heart disease, very high blood pressure, bowel block, ulcer disease, or trouble passing urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11299 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10373=[""].join("\n");
var outline_f10_8_10373=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142725\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011617\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011619\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011618\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011623\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011624\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011626\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011621\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011622\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011627\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011628\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3222?source=related_link\">",
"      Brompheniramine, pseudoephedrine, and dextromethorphan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_8_10374="Approach to the patient with incidental gallstones";
var content_f10_8_10374=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with incidental gallstones",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10374/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10374/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10374/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10374/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10374/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10374/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/8/10374/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstone disease is one of the most common and costly of all digestive diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the approach to the patient with an incidental finding of gallstones. The approach to patients with symptomatic gallstones or with complications of gallstone disease (such as cholecystitis and pancreatitis) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link\">",
"     \"Uncomplicated gallstone disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=see_link\">",
"     \"Approach to the patient with suspected choledocholithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology of acute pancreatitis\", section on 'Gallstones'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF ASYMPTOMATIC GALLSTONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A great deal has been learned about the epidemiology of and risk factors for gallstones (",
"    <a class=\"graphic graphic_table graphicRef81139 \" href=\"UTD.htm?7/47/7932\">",
"     table 1",
"    </a>",
"    ). Ultrasonography has played a major role in this process, providing a rapid, risk-free method of screening large populations. Prior to the availability of ultrasound, most studies relied on highly selective autopsy data and limited oral cholecystography.",
"   </p>",
"   <p>",
"    The routine use of ultrasonography for the evaluation of abdominal pain, pelvic disease, and abnormal liver function tests has led to the identification of incidental gallstones in many patients (",
"    <a class=\"graphic graphic_table graphicRef57092 \" href=\"UTD.htm?0/50/814\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The majority of these patients have no symptoms attributable to the gallstones; however, approximately 20 percent will become symptomatic during up to 15 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The likelihood of continued symptoms or the development of other complications of gallstone disease (such as cholecystitis, pancreatitis, and choledocholithiasis) is substantially higher in patients who have developed symptomatic gallstones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link&amp;anchor=H2#H2\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a landmark study, for example, the entire population of a town in Italy (Sirmione) was screened by ultrasound for the presence of gallstones or gallstone related disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/2\">",
"     2",
"    </a>",
"    ]. Of 132 subjects with gallstones who were identified, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall prevalence of gallstones was 7 percent, was higher in women than men (9 versus 5 percent), and increased with advancing age.",
"     </li>",
"     <li>",
"      Patients with gallstones were significantly more likely to suffer from biliary pain compared with patients without gallstones (22 versus 2 percent).",
"     </li>",
"     <li>",
"      Eighty-two percent of patients found to have gallstones were not aware of having gallstones prior to the study; 16 percent of these patients developed symptoms during 10 years of follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were reported in a cross-sectional study in Rome that included 151 patients who were identified as having gallstones by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/4\">",
"     4",
"    </a>",
"    ]. At study entry, 22 percent had symptoms attributable to gallstone disease. During 10 years of follow-up, the cumulative probability of developing biliary colic among the asymptomatic individuals was 26 percent.",
"   </p>",
"   <p>",
"    The prevalence of gallstones and gallstone related disease in the United States was estimated based upon data from the third National Health and Nutrition Examination Survey (NHANES III), in which gallbladder ultrasonography was performed in a representative sample of more than 14,000 people [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/5\">",
"     5",
"    </a>",
"    ]. The overall prevalence of gallstones and gallbladder disease (ie, either the presence of gallstones or ultrasonographic evidence of cholecystectomy) was 5.5 and 7.9 percent respectively in men, and 8.6 and 16.6 percent, respectively in women. As expected, the prevalence varied depending upon age and ethnicity. The prevalence of gallstones and gallbladder disease was highest in men and women between the ages of 60 to 74 (",
"    <a class=\"graphic graphic_table graphicRef57092 \" href=\"UTD.htm?0/50/814\">",
"     table 2",
"    </a>",
"    ), and among Mexican Americans compared with non-Hispanic whites and blacks.",
"   </p>",
"   <p>",
"    In a study from Norway, 1371 randomly selected patients who had not had a cholecystectomy underwent an ultrasound examination. Incidental gallstones were discovered in 285 (21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/6\">",
"     6",
"    </a>",
"    ]. Twenty-four years later, a follow-up study was performed that included 134 of the patients who had gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/7\">",
"     7",
"    </a>",
"    ]. The patients underwent either a clinical examination (89 patients) or answered a mail or telephone questionnaire (45 patients). Gallstones were present on ultrasound in 25 of 89 patients (28 percent overall, 31 percent of women and 25 percent of men). The mean age of the 89 patients at the time of the initial examination was 44 years for women and 45 years for men. There was no association between the number or size of gallstones at the original examination and the demonstration of gallstones at follow-up. Nine of 134 patients (7 percent) had undergone cholecystectomy, as had 5 of 91 patients who had died prior to follow-up (6 percent). During follow-up, 44 percent developed abdominal pain, and 29 percent had what were deemed to be functional abdominal complaints.",
"   </p>",
"   <p>",
"    Patients who have symptomatic gallstones represent a separate category. These patients are likely to develop recurrent symptoms, and are at increased risk for the development of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In an illustrative study that included 305 patients with gallstones, 70 percent of those with a history of biliary colic developed recurrent symptoms within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/8\">",
"     8",
"    </a>",
"    ]. Other complications of gallstones disease occur at a rate of approximately 1 to 2 percent per year in most studies. The majority of patients who present with these complications have a prior history of biliary colic.",
"   </p>",
"   <p>",
"    These data demonstrate that the majority of patients found to have incidental gallstones will remain asymptomatic and that with prolonged follow-up, many patients will not have gallstones demonstrated on follow-up examination. When symptoms occur, they are usually biliary colic rather than complications of gallstone disease.",
"   </p>",
"   <p>",
"    Gallstones are sometimes implicated as the source of symptoms in patients with dyspepsia. However, such an association should be made cautiously since gallstones may silently coexist in patients with dyspepsia, and other causes of dyspepsia are more common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ROLE OF PROPHYLACTIC CHOLECYSTECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective trials of therapy, either surgical or medical, for asymptomatic gallstones. However, decision analysis models have shown no benefit of a prophylactic cholecystectomy. In one study, for example, decision analysis was used to compare the consequences of prophylactic cholecystectomy with expectant management in patients with asymptomatic gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/10\">",
"     10",
"    </a>",
"    ]. Prophylactic cholecystectomy slightly decreased survival and was",
"    <strong>",
"     not",
"    </strong>",
"    associated with an appreciable gain in discounted life years gained. Although this model was constructed prior to the development of laparoscopic cholecystectomy, it is unlikely that the laparoscopic approach would significantly alter the results based upon sensitivity analysis included in the study.",
"   </p>",
"   <p>",
"    Thus, prophylactic cholecystectomy is",
"    <strong>",
"     not",
"    </strong>",
"    indicated in most patients with asymptomatic gallstones. Possible exceptions include patients who are at increased risk for gallbladder carcinoma or gallstone complications, in whom prophylactic cholecystectomy or incidental cholecystectomy at the time of another abdominal operation can be considered. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Patients at increased risk of complications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15082?source=see_link\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cholecystectomy is recommended in patients with symptomatic gallstones who are good surgical candidates. Medical therapy can be considered in symptomatic patients who are not good candidates for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link&amp;anchor=H25#H25\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14582?source=see_link\">",
"     \"Patient selection for the nonsurgical treatment of gallstone disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATIENTS AT INCREASED RISK OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with asymptomatic gallstones may be at increased risk from complications and may therefore require special consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstones are more common in diabetic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    .) Predominantly anecdotal evidence suggests that diabetic patients are at increased risk for the development of severe gangrenous cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the magnitude of the risk and the risks and costs of cholecystectomy",
"    <strong>",
"     do not",
"    </strong>",
"    warrant prophylactic cholecystectomy in diabetics with asymptomatic gallstones. One study, for example, identified 70 patients with gallstones and diabetes mellitus who were followed for five years; 47 (70 percent) were asymptomatic at study entry, while the others had a history of biliary colic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/12\">",
"     12",
"    </a>",
"    ]. During follow-up, 10 percent of the initially asymptomatic patients developed biliary colic and 4 percent developed other gallstone complications; these values are similar to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. By contrast, 48 percent of patients who were initially symptomatic either continued to have biliary colic (40 percent) or developed acute cholecystitis (8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patients at increased risk for biliary cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of cholangiocarcinoma and gallbladder carcinoma has been associated with certain disorders of the biliary tree, and in some ethnic groups (such as Native Americans). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=see_link\">",
"     \"Epidemiology, pathogenesis, and classification of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15082?source=see_link\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\"",
"    </a>",
"    .) These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Choledochal cysts (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=see_link\">",
"       \"Biliary cysts\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Caroli's disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2902?source=see_link\">",
"       \"Caroli disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anomalous pancreatic ductal drainage (in which the pancreatic duct drains into the common bile duct)",
"     </li>",
"     <li>",
"      Gallbladder adenomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13209?source=see_link\">",
"       \"Gallbladder polyps and cholesterolosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Porcelain gallbladder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39668?source=see_link\">",
"       \"Porcelain gallbladder\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prophylactic cholecystectomy may be indicated in many of these patients. If abdominal surgery is planned for another indication, an incidental cholecystectomy should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pigment gallstones are common and often asymptomatic in patients with sickle cell disease. Prophylactic cholecystectomy is not recommended, but an incidental cholecystectomy should be considered if abdominal surgery is being performed for other reasons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hereditary spherocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authorities recommend combined prophylactic splenectomy and cholecystectomy in young asymptomatic patients with hereditary spherocytosis if gallstones are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=see_link&amp;anchor=H4#H4\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\", section on 'Gallstone formation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gastric bypass surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidly obese patients who have undergone gastric bypass surgery, a form of bariatric surgery, have a high incidence of developing gallstones (greater than 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10374/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. An incidental cholecystectomy is recommended by some at the time of surgery, though the issue is controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology of and risk factors for gallstones\", section on 'Rapid weight loss'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H31#H31\">",
"     \"Complications of bariatric surgery\", section on 'Cholelithiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=see_link\">",
"       \"Patient information: Gallstones (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=see_link\">",
"       \"Patient information: Gallbladder removal (cholecystectomy) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"       \"Patient information: Gallstones (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients found to have incidental gallstones will remain asymptomatic. When symptoms occur, they are usually biliary colic rather than complications of gallstone disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history of asymptomatic gallstones'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardinal symptom of gallstones is biliary colic. Biliary colic is a moderately severe crescendo type pain in the right upper quadrant radiating to the back and right shoulder, which may be accompanied by nausea. Despite its name, the pain is usually steady and not colicky. Pain may be brought on after ingestion of fatty foods. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link&amp;anchor=H2#H2\">",
"       \"Uncomplicated gallstone disease in adults\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gallstones are sometimes implicated as the source of symptoms in patients with dyspepsia. However, such an association should be made cautiously, since gallstones may silently coexist in patients with dyspepsia, and other causes of dyspepsia are more common. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history of asymptomatic gallstones'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend against prophylactic cholecystectomy in most patients with asymptomatic gallstones (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Possible exceptions include patients who are at increased risk for gallbladder carcinoma or gallstone complications, in whom prophylactic cholecystectomy or incidental cholecystectomy at the time of another abdominal operation can be considered. Although patients with diabetes mellitus may have an increased risk of complications, the magnitude of the risk does not warrant prophylactic cholecystectomy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Role of prophylactic cholecystectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Patients at increased risk of complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Capocaccia L, the GREPCO group. Clinical symptoms and gallstone disease: Lessons from a population study. In: Epidemiology and prevention of gallstone disease, Capocaccia L, Ricci G, Angelico F, Attili AF (Eds), Lancaster MTP Press, 1984. p.153.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/2\">",
"      Barbara L, Sama C, Morselli Labate AM, et al. A population study on the prevalence of gallstone disease: the Sirmione Study. Hepatology 1987; 7:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/3\">",
"      Gracie WA, Ransohoff DF. The natural history of silent gallstones: the innocent gallstone is not a myth. N Engl J Med 1982; 307:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/4\">",
"      Attili AF, De Santis A, Capri R, et al. The natural history of gallstones: the GREPCO experience. The GREPCO Group. Hepatology 1995; 21:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/5\">",
"      Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999; 117:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/6\">",
"      Glambek I, Kvaale G, Arnesj&ouml; B, S&oslash;reide O. Prevalence of gallstones in a Norwegian population. Scand J Gastroenterol 1987; 22:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/7\">",
"      Schmidt M, Hausken T, Glambek I, et al. A 24-year controlled follow-up of patients with silent gallstones showed no long-term risk of symptoms or adverse events leading to cholecystectomy. Scand J Gastroenterol 2011; 46:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/8\">",
"      Thistle JL, Cleary PA, Lachin JM, et al. The natural history of cholelithiasis: the National Cooperative Gallstone Study. Ann Intern Med 1984; 101:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/9\">",
"      Friedman GD, Raviola CA, Fireman B. Prognosis of gallstones with mild or no symptoms: 25 years of follow-up in a health maintenance organization. J Clin Epidemiol 1989; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/10\">",
"      Ransohoff DF, Gracie WA, Wolfenson LB, Neuhauser D. Prophylactic cholecystectomy or expectant management for silent gallstones. A decision analysis to assess survival. Ann Intern Med 1983; 99:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/11\">",
"      Reiss R, Nudelman I, Gutman C, Deutsch AA. Changing trends in surgery for acute cholecystitis. World J Surg 1990; 14:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/12\">",
"      Del Favero G, Caroli A, Meggiato T, et al. Natural history of gallstones in non-insulin-dependent diabetes mellitus. A prospective 5-year follow-up. Dig Dis Sci 1994; 39:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/13\">",
"      Bragg LE, Thompson JS. Concomitant cholecystectomy for asymptomatic cholelithiasis. Arch Surg 1989; 124:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/14\">",
"      Diehl AK. Gallstone size and the risk of gallbladder cancer. JAMA 1983; 250:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/15\">",
"      Shiffman ML, Sugerman HJ, Kellum JM, et al. Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity. Am J Gastroenterol 1991; 86:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10374/abstract/16\">",
"      Wattchow DA, Hall JC, Whiting MJ, et al. Prevalence and treatment of gall stones after gastric bypass surgery for morbid obesity. Br Med J (Clin Res Ed) 1983; 286:763.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 673 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-B3AA2FA6DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10374=[""].join("\n");
var outline_f10_8_10374=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY OF ASYMPTOMATIC GALLSTONES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ROLE OF PROPHYLACTIC CHOLECYSTECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATIENTS AT INCREASED RISK OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patients at increased risk for biliary cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hereditary spherocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gastric bypass surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/673\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/673|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/47/7932\" title=\"table 1\">",
"      Risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/50/814\" title=\"table 2\">",
"      Prevalence of gallstones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=related_link\">",
"      Approach to the patient with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9977?source=related_link\">",
"      Biliary cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2902?source=related_link\">",
"      Caroli disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=related_link\">",
"      Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15082?source=related_link\">",
"      Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13209?source=related_link\">",
"      Gallbladder polyps and cholesterolosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=related_link\">",
"      Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=related_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=related_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=related_link\">",
"      Patient information: Gallstones (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14582?source=related_link\">",
"      Patient selection for the nonsurgical treatment of gallstone disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39668?source=related_link\">",
"      Porcelain gallbladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=related_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_8_10375="COX-2 inhibitors and gastroduodenal toxicity — major clinical trials";
var content_f10_8_10375=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10375/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10375/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10375/contributors\">",
"     Shounak Das, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10375/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10375/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10375/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10375/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/8/10375/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary effect of nonsteroidal antiinflammatory drugs (NSAIDs) is to inhibit cyclooxygenase (prostaglandin H synthase, or PGHS), thereby impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes. Two related isoforms of the cyclooxygenase (COX) enzyme have been described: COX-1 (PGHS-1) and COX-2 (PGHS-2). COX-1 is involved in gastric cytoprotection. It had been proposed that the ideal NSAID would inhibit the inducible COX-2 isoform (thereby decreasing inflammation) without having any effect on the constitutive COX-l isoform (thereby minimizing gastric toxicity) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One NSAID that selectively inhibits COX-2,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , is currently approved by the US Food and Drug Administration (FDA) (",
"    <a class=\"graphic graphic_table graphicRef54253 \" href=\"UTD.htm?38/16/39180\">",
"     table 1",
"    </a>",
"    ). Rofecoxib is a COX-2 inhibitor that was removed due to an increased risk of stroke and myocardial infarctions with long-term use. Valdecoxib was removed because of concerns of cardiovascular risk and reports of Stevens-Johnson syndrome. An increased risk of cardiovascular events has also been observed with celecoxib, especially in higher doses, although it continues to be available. These observations led the FDA to issue warnings regarding the use of these drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other COX-2 inhibitors are available in some countries. Parecoxib is a water soluble prodrug that is converted to valdecoxib. Etoricoxib and lumiracoxib are available in some countries. These drugs have at least a 200- to 300-fold selectivity for inhibition of COX-2 over COX-1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will summarize the major clinical trials that have focused on the gastroduodenal protective effects of the COX-2 inhibitors. An approach to patients at risk for gastroduodenal toxicity is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .) An overview of COX-2 inhibitors is also available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CELECOXIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     Celecoxib",
"    </a>",
"    was approved based upon the results of five clinical trials (some of which have been published only in preliminary form) involving more than 5200 patients with osteoarthritis or rheumatoid arthritis in which its efficacy and toxicity were compared to nonselective nonsteroidal antiinflammatory drugs (NSAIDs) and placebo. These data demonstrate that celecoxib produced comparable analgesia and antiinflammatory effects to nonselective NSAIDs.",
"   </p>",
"   <p>",
"    Two trials that used an endpoint of endoscopically detected ulcers found a lower incidence in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    compared to nonselective NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the published studies included a total of 688 patients with rheumatoid arthritis who completed a controlled trial comparing various doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      or placebo for 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/2\">",
"       2",
"      </a>",
"      ]. All doses of celecoxib and naproxen improved signs and symptoms of arthritis compared to placebo. The incidence of endoscopically determined gastroduodenal ulcers among patients taking celecoxib was similar to placebo (approximately 4 percent) and was much lower than observed with naproxen (26 percent).",
"     </li>",
"     <li>",
"      Similar results were found in a second study of 655 patients with rheumatoid arthritis, which compared the efficacy and gastrointestinal toxicity of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other trials focused on a more relevant endpoint of clinically evident ulcers (symptomatic ulcers and ulcer complications) have been conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CLASS study, involving 8059 patients, found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      was associated with significantly fewer symptomatic ulcers and ulcer complications than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      during the first six months of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/4\">",
"       4",
"      </a>",
"      ]. In addition, celecoxib was associated with less liver toxicity, hypertension, and edema compared to the nonselective NSAIDs.",
"      <br/>",
"      <br/>",
"      However, data from this study have been the subject of reanalysis. Of note, during the second six months of treatment (a time period that was not included in the published report) the incidence of ulcer complications was higher in the celecoxib than in the ibuprofen or diclofenac treated groups. As a result, at the end of a year of observation, there were no significant differences in incidence of ulcer complications among the three groups [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/5\">",
"       5",
"      </a>",
"      ]. Possible reasons for the apparent failure of celecoxib to reduce the risk of ulcer complications in this study include the use of low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in approximately 20 percent of patients, the use of a relatively high dose of celecoxib (800 mg per day), and that it was compared to NSAIDs with a relatively low potential for causing such side effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A second trial (the SUCCESS-I study) included a total of 13,274 patients with osteoarthritis from 39 countries, 8,800 of whom were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      (100 or 200 mg twice daily for 12 weeks) and 4394 of whom were assigned to a nonselective NSAID (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      50 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      500 mg twice daily for 12 weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/6\">",
"       6",
"      </a>",
"      ]. The drugs were similarly effective in treating osteoarthritis. Despite the two-fold larger size of the combined celecoxib groups as compared to the combined NSAID groups, the number of clinically significant ulcers was equal in the two groups (18 ulcers in each group, OR 2 for NSAID group, 95% CI 1.04-3.86). Only nine ulcer complications occurred in this study, seven in the NSAID groups, and two in the celecoxib groups (p = 0.008; OR 7 for NSAID group, 95% CI 1.5-33.8). There were fewer complications only in patients not taking concomitant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (six in the NSAID group and one in the celecoxib group) and not in patients taking aspirin (one ulcer complication in each group). The study was underpowered to detect a difference in cardiovascular events between the groups. However, there were 10 myocardial infarctions in the larger combined celecoxib group as compared to one myocardial infarction in the twofold smaller combined NSAID group (OR 0.2 for NSAID group, 95% CI 0.03-1.56).",
"     </li>",
"     <li>",
"      The CONDOR study compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      . The primary endpoint was a composite of clinically significant upper or lower gastrointestinal events. In this study, the diclofenac and omeprazole group was associated with an increased risk of gastrointestinal events compared to the celecoxib group (hazard ratio 4.3, 95% CI 2.6-7.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VALDECOXIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although valdecoxib is no longer available, data on valdecoxib safety suggested a substantially lower risk of gastroduodenal damage compared to nonselective nonsteroidal antiinflammatory drugs (NSAIDs). A pooled analysis of several studies comparing valdecoxib to nonselective NSAIDs in patients with osteoarthritis or rheumatoid arthritis found that valdecoxib was associated with a significantly lower risk of ulcer complications (0.68 versus 1.96 percent for all patients and 0.29 versus 2.08 percent for non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    users) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/8\">",
"     8",
"    </a>",
"    ]. In long-term open-label studies, the annual incidence of ulcer complications was estimated to be 0.39 percent (0.2 percent for non-aspirin users).",
"   </p>",
"   <p>",
"    Valdecoxib was removed from the market because of concerns related to an increase in cardiovascular events and reports of Stevens-Johnson syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PARECOXIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of short-term parenteral administration of parecoxib, which is converted to valdecoxib, was assessed in an endoscopic study of 92 healthy elderly people ages 65 to 75 who were randomly assigned to receive one of three interventions for seven days: intravenous parecoxib (40 mg twice daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    (15 mg four times daily), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/9\">",
"     9",
"    </a>",
"    ]. Endoscopic evaluation revealed no gastric or duodenal ulceration among those who received placebo or parecoxib compared to ulcers in 23 percent of subjects in the ketorolac group. Studies of parecoxib are required to assess its role in treating pain or inflammation in patients needing a parenteral analgesic.",
"   </p>",
"   <p>",
"    Parecoxib is available in much of Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETORICOXIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several controlled trials have compared etoricoxib to nonselective nonsteroidal antiinflammatory drugs (NSAIDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/10\">",
"     10",
"    </a>",
"    ]. A combined analysis evaluated ten phase",
"    <span class=\"nowrap\">",
"     II/III",
"    </span>",
"    randomized trials of etoricoxib in the treatment of osteoarthritis, rheumatoid arthritis, and chronic low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/11\">",
"     11",
"    </a>",
"    ]. In this analysis, the number of confirmed gastroduodenal events (defined as a clinical, not endoscopic, diagnosis of peptic ulcer disease) was significantly lower in patients who received etoricoxib compared with those treated with nonselective NSAIDs (0.95 versus 2.24 percent, RR for etoricoxib 0.42; 95% CI 0.26-0.67).",
"   </p>",
"   <p>",
"    Etoricoxib is approved in some countries but not in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LUMIRACOXIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumiracoxib, a highly selective COX-2 inhibitor, is a phenyl-acetic acid compound and not a tricyclic compound like the other coxibs. A combined report of two studies with identical design (the \"TARGET\" trial) included 18,325 patients with osteoarthritis who were randomly assigned to lumiracoxib (400 mg once daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (500 mg twice daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (800 mg three times daily) for 52 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/12\">",
"     12",
"    </a>",
"    ]. In the patients who were not taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , the cumulative incidence of ulcer complications (ie, bleeding, perforation, or obstruction) was significantly lower with lumiracoxib than with naproxen or ibuprofen (hazard ratio 0.21, 95% CI 0.12-0.37). However, there was no reduction in ulcer complications in patients concurrently taking aspirin.",
"   </p>",
"   <p>",
"    There were more myocardial infarctions (MIs) in the lumiracoxib group compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (0.38 versus 0.21 percent), but the differences were not statistically significant. However, the study excluded most patients with known, symptomatic coronary artery disease, a group at increased risk for adverse cardiovascular events. Furthermore, the study may have been underpowered to detect a difference in the rates of myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, the risk of gastroduodenal ulceration with lumiracoxib was similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    and significantly less than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , but the study did not address cardiovascular risks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lumiracoxib was associated with hepatotoxicity in Australia and was taken off the market there as well as in several other countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ROFECOXIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rofecoxib was found to have a 50 percent relative risk reduction in gastrointestinal events compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    in rheumatoid arthritis patients in the VIGOR trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/15\">",
"     15",
"    </a>",
"    ]. Nevertheless, in a three-year placebo-controlled trial for colorectal adenoma chemoprevention, rofecoxib was associated with an increased incidence in clinically relevant upper gastrointestinal bleeding compared with placebo (RR 4.9, 95% CI 1.98-14.54) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/16\">",
"     16",
"    </a>",
"    ]. These findings underscore that the COX-2 inhibitors may be safer than conventional nonsteroidal antiinflammatory drugs (NSAIDs) for reduction in the risk of gastrointestinal bleeding, but are still associated with an increased risk.",
"   </p>",
"   <p>",
"    Rofecoxib was removed from the market because of an increased risk of myocardial infarctions and stroke associated with long-term use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONCURRENT ASPIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential gastroduodenal sparing effect of selective COX-2 inhibitors may be reduced by concurrent low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy for primary or secondary prevention of cardiovascular or cerebrovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two mechanisms have been proposed to account for the loss of gastroduodenal sparing effect of selective COX-2 inhibitors with concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use. First, it may be related directly to the effect of aspirin, which blocks COX-1 in the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/17\">",
"     17",
"    </a>",
"    ]. Second, aspirin allows COX-2 to produce gastroprotective acids such as lipoxins, which help minimize gastric damage due to aspirin; this gastroprotective effect can be abolished by a COX-2 inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the CLASS study, similar rates of ulcers and ulcer complications were noted among those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      plus low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      as among patients receiving a nonselective nonsteroidal antiinflammatory drug (NSAID) plus aspirin (2.02 and 2.12 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/4\">",
"       4",
"      </a>",
"      ]. Thus, patients receiving both aspirin and a selective COX-2 inhibitor may require prophylactic antiulcer therapy if they are at risk for gastroduodenal toxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another study included 1615 patients with osteoarthritis who were randomly assigned to placebo, enteric-coated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (81 mg daily), enteric-coated aspirin (81 mg daily) plus rofecoxib (25 mg daily), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (800 mg three times daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/19\">",
"       19",
"      </a>",
"      ]. The 12-week cumulative incidence of endoscopically detected ulcers was significantly higher in the rofecoxib plus aspirin group than in the aspirin alone group (16.1 percent versus 7.3 percent). The endoscopic ulcer rate of 16.1 percent with rofecoxib plus aspirin was similar to the rate in the ibuprofen group (17.1 percent). The rate of ulcers with low-dose aspirin alone (7.3 percent) was higher than the incidence with placebo (5.8 percent), but the difference was not statistically significant. The authors concluded that the addition of rofecoxib to low-dose aspirin increased the incidence of endoscopic ulcers to a rate comparable to nonselective NSAIDs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conversely, other studies suggest that GI toxicity of COX-2 inhibitors may be less than that of nonselective NSAIDs even with concurrent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized controlled trial addressing (as the primary endpoint) cardiovascular toxicity of the COX-2 inhibitor etoricoxib versus the nonselective NSAID",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      showed less GI toxicity in the etoricoxib arm regardless of proton pump inhibitor (PPI) or ASA co-administration in a prespecified analysis of GI toxicities performed separately from the primary outcome analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/20\">",
"       20",
"      </a>",
"      ]. However, this benefit only held true for uncomplicated GI events; there was no difference between the two groups for complicated GI events.",
"     </li>",
"     <li>",
"      Two randomized controlled endoscopic studies assessed the occurrence of gastroduodenal ulcers in healthy volunteers given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      together with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      , or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Although the incidence of ulcers was increased with celecoxib compared to placebo, significantly fewer ulcers were found with celecoxib than with naproxen.",
"     </li>",
"     <li>",
"      A Cochrane review concluded that COX-2 inhibitors appear to offer greater upper GI safety than nonselective NSAIDs, but that the coadministration of acetylsalicylic acid might reduce this safety advantage [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMBINED USE OF COX-2 INHIBITORS AND PPIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients considered to be at exceptionally high risk for peptic ulcer disease, combining a selective COX-2 inhibitor with a PPI may confer added protection against GI toxicity. A randomized controlled trial of H. pylori negative patients who had been hospitalized for upper GI bleeding associated with nonselective nonsteroidal antiinflammatory drugs (NSAID) use found that after 13 months none of the patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    in combination with a PPI had recurrent bleeding compared to 9 percent of patients on celecoxib and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10375/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212272939\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary effect of nonsteroidal antiinflammatory drugs (NSAIDs) is to inhibit cyclooxygenase, thereby impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes. There are two isoforms of the cyclooxygenase enzyme. The COX-1 isoform is involved in gastric cytoprotection, and the COX-2 isoform decreases inflammation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall, COX-2 inhibitors appear to be safer than conventional NSAIDs for reduction in the risk of gastrointestinal bleeding, but are still associated with an increased risk of bleeding compared to placebo. The potential gastroduodenal sparing effect of selective COX-2 inhibitors may be reduced by concurrent low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Concurrent aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients considered to be at exceptionally high risk for peptic ulcer disease, combining a selective COX-2 inhibitor with a PPI may confer added protection against GI toxicity. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Combined use of COX-2 inhibitors and PPIs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       Celecoxib",
"      </a>",
"      is currently approved by the Food and Drug Administration (FDA). Parecoxib, etoricoxib, and lumiracoxib are available in some countries.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       Celecoxib",
"      </a>",
"      produces comparable analgesia and antiinflammatory effects to nonselective NSAIDs. Compared to nonselective NSAIDs, celecoxib has been associated with fewer endoscopically detectable, but not necessarily clinically significant gastric and duodenal ulcers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Celecoxib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Valdecoxib has been associated with a substantially lower risk of gastroduodenal damage compared to nonselective NSAIDs. However, valdecoxib was removed from the market in the United States because of concerns related to an increase in cardiovascular events and reports of Stevens-Johnson syndrome. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Valdecoxib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parecoxib is converted to active metabolite valdecoxib. Although short-term parenteral administration of parecoxib has been associated with a lower risk of gastric or duodenal ulceration compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      , further studies are required to assess the role of parecoxib in treating pain or inflammation in patients needing a parenteral analgesic. Parecoxib is available in much of Europe but not in the United States. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Parecoxib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Etoricoxib has been associated with an approximately 50 percent lower incidence of investigator-reported and confirmed adverse upper GI events compared to treatment with nonselective NSAIDs in phase",
"      <span class=\"nowrap\">",
"       II/III",
"      </span>",
"      clinical studies. Etoricoxib is approved in some countries but not in the United States. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etoricoxib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumiracoxib is a highly selective COX-2 inhibitor. In one study, the cumulative incidence of ulcer complications (ie, bleeding, perforation, or obstruction) was significantly lower with lumiracoxib than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , in patients who were not taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . Reductions in ulcer complications were not apparent in patients concurrently taking aspirin.",
"      <br/>",
"      <br/>",
"      Lumiracoxib was associated with more myocardial infarctions (MIs) than naproxen. Although this difference was not statistically significant, the study was underpowered to detect a difference in the rates of myocardial infarction. Lumiracoxib has also been associated with hepatotoxicity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lumiracoxib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rofecoxib was found to have a 50 percent relative risk reduction in gastrointestinal events compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      in rheumatoid arthritis patients in the VIGOR trial. However, in a three-year, placebo-controlled trial for colorectal adenoma chemoprevention, rofecoxib was associated with an increased incidence in clinically relevant upper gastrointestinal bleeding compared with placebo. Rofecoxib was removed from the market because of an increased risk of MIs and stroke associated with long-term use. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Rofecoxib'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/1\">",
"      Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/2\">",
"      Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/3\">",
"      Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/4\">",
"      Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/5\">",
"      J&uuml;ni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/6\">",
"      Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006; 119:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/7\">",
"      Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/8\">",
"      Goldstein JL, Eisen GM, Agrawal N, et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 2004; 20:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/9\">",
"      Stoltz RR, Harris SI, Kuss ME, et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol 2002; 97:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/10\">",
"      Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/11\">",
"      Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/12\">",
"      Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/13\">",
"      Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet 2004; 364:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/14\">",
"      Hawkey CC, Svoboda P, Fiedorowicz-Fabrycy IF, et al. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol 2004; 31:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/15\">",
"      Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/16\">",
"      Lanas A, Baron JA, Sandler RS, et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 2007; 132:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/17\">",
"      Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/18\">",
"      Fiorucci S, Santucci L, Gresele P, et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003; 124:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/19\">",
"      Laine L, Maller ES, Yu C, et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004; 127:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/20\">",
"      Combe B, Swergold G, McLay J, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009; 48:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/21\">",
"      Goldstein JL, Lowry SC, Lanza FL, et al. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 2006; 23:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/22\">",
"      Goldstein JL, Aisenberg J, Zakko SF, et al. Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial. Dig Dis Sci 2008; 53:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/23\">",
"      Rostom A, Muir K, Dub&eacute; C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10375/abstract/24\">",
"      Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369:1621.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10375=[""].join("\n");
var outline_f10_8_10375=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1212272939\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CELECOXIB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VALDECOXIB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PARECOXIB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETORICOXIB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LUMIRACOXIB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ROFECOXIB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONCURRENT ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMBINED USE OF COX-2 INHIBITORS AND PPIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1212272939\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/10\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/10|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/16/39180\" title=\"table 1\">",
"      Selectivity of NSAIDs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_8_10376="Congenital third degree (complete) atrioventricular block";
var content_f10_8_10376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital third degree (complete) atrioventricular block",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10376/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10376/contributors\">",
"     William H Sauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10376/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10376/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10376/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/8/10376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an impulse from the atria to the ventricles due to an anatomical or functional impairment in the conduction system. The conduction disturbance can be transient or permanent. The conduction can be delayed, intermittent, or absent. The commonly used terminology includes first degree (slowed conduction without missed beats), second degree (missed beats, often in a regular pattern, eg, 2:1, 3:2, or higher degrees of block), and third degree or complete AV block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=see_link\">",
"     \"ECG tutorial: Atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Congenital third degree, or complete, heart block (CHB) was first described in 1901 by Morquio, who also noted the familial occurrence and the association with Stokes-Adams attacks and death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of fetal bradycardia (40 to 80 beats per minute) as a manifestation of CHB was first noted in 1921 and is the initial sign of this disorder in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of congenital CHB in the general population varies between 1 in 15,000 to 1 in 22,000 live-born infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology, presentation, treatment, and prognosis associated with congenital CHB will be presented here. Discussions of the etiologies of acquired AV block as well as non-congenital complete AV block are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal lupus, previously known as maternal lupus and caused by maternal antibodies that cross the placenta, is responsible for 60 to 90 percent of cases of congenital CHB overall [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. It accounts for almost all cases presenting in utero or the neonatal period, but for only a few cases occurring later (5 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes include myocarditis and various structural cardiac defects, particularly congenitally corrected transposition of the great arteries, atrioventricular discordance, or polysplenia with atrioventricular canal defect. Several hereditary disorders have also been identified. (See",
"    <a class=\"local\" href=\"#H18519160\">",
"     'Non-immune congenital AV block'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology of atrioventricular block\", section on 'Familial disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Neonatal lupus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart block in neonatal lupus primarily presents in utero or in the neonate; it is a much less common cause of congenital complete heart block presenting later in childhood (90 to 95 percent versus 5 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. Other manifestations of neonatal lupus include rash and less often other cardiac abnormalities, hepatobiliary disease, and thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link&amp;anchor=H8#H8\">",
"     \"Neonatal lupus\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neonatal lupus results from transplacental passage of maternal",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies. Among women with such antibodies, complete heart block occurs in approximately 2 percent of pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Once a woman has given birth to an infant with congenital heart block, the recurrence rate of congenital heart block in subsequent pregnancies is about 15 percent; another 6 percent have an isolated rash consistent with neonatal lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sinoatrial (SA) node also may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. Sinus bradycardia has been described in 3.8 percent of fetuses but is usually not permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18519160\">",
"    <span class=\"h2\">",
"     Non-immune congenital AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients without neonatal lupus or significant congenital structural heart disease, familial inheritance of conduction disease is often responsible for AV block.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective cohort of 141 children with AV block diagnosed in utero or up to age 15 years (51 percent female, 84 percent asymptomatic, 71 percent with complete AV block on presentation, with an additional 21 percent progressing from incomplete to complete AV block), 112 patients (79 percent) received permanent pacemakers, most prophylactically in asymptomatic patients (70 of 112 patients [63 percent]) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/12\">",
"       12",
"      </a>",
"      ]. Over an average follow-up of 11.6 years, there were no deaths or instances of dilated cardiomyopathy.",
"     </li>",
"     <li>",
"      Using the same 141 patient cohort, familial screening electrocardiograms (ECGs) were obtained from 130 parents and were compared with 130 matched healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/13\">",
"       13",
"      </a>",
"      ]. Parents of the children with AV block were significantly more likely to have conduction abnormalities compared with healthy controls, including complete or incomplete right bundle branch block (39 versus 2 percent), complete or incomplete left bundle branch block (15 versus 3 percent), and PR prolongation (19 versus 0 percent). The authors estimated that there was a 91 percent likelihood that isolated conduction disturbances were inherited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6036308\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, congenital complete heart block is characterized pathologically by fibrous tissue that either replaces the AV node and its surrounding tissue or by an interruption between the atrial myocardium and the atrioventricular node (AV node); other lesions that can occur include congenital absence of the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/10,14-21\">",
"     10,14-21",
"    </a>",
"    ]. The net effect is that the block is usually at the level of the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/15,17,19,22,23\">",
"     15,17,19,22,23",
"    </a>",
"    ]. The heart is otherwise normal pathologically in children with neonatal lupus and certain other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/9,24\">",
"     9,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among infants with CHD due to neonatal lupus,",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies bind to fetal cardiac tissue, leading to autoimmune injury of the atrioventricular (AV) node and its surrounding tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/8,10,25\">",
"     8,10,25",
"    </a>",
"    ]. Both",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     La/SSB",
"    </span>",
"    antigens are abundant in fetal heart tissue between 18 and 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/25\">",
"     25",
"    </a>",
"    ]. Apoptosis induces translocation of",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     La/SSB",
"    </span>",
"    to the surface of fetal cardiomyocytes; anti-Ro and anti-La antibodies then bind to the surface of the fetal cardiocytes and induce the release of tumor necrosis factor by macrophages, which then results in fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to inducing tissue damage,",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies inhibit calcium channel activation or the cardiac L- and T- type calcium channels themselves; L-type channels are crucial to action potential propagation and conduction in the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations of congenital heart block vary with the age at presentation. Patients with the neonatal lupus syndrome tend to present earlier than those with CHB not due to neonatal lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, patients with the neonatal lupus syndrome may have a variety of other cardiac abnormalities, including ventricular septal defect and endocardial fibroelastosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6,30\">",
"     6,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link&amp;anchor=H12#H12\">",
"     \"Neonatal lupus\", section on 'Other cardiac abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Presentation in utero",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital heart block may present with fetal bradycardia between 18 and 28 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Almost all of these cases (95 percent in one series) are due to neonatal lupus, as demonstrated by the presence of",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies in the maternal serum [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. In utero detection is made by echocardiography, which can estimate the fetal PR interval [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/31\">",
"     31",
"    </a>",
"    ]. Associated complications in utero can include hydrops fetalis, endocardial fibroelastosis, pericardial effusion, and spontaneous intrauterine fetal death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. In one report, among 29 cases diagnosed in utero, there was one therapeutic abortion and six intrauterine fetal deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]; a lower rate of intrauterine death (6 of 87) was seen in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/9\">",
"     9",
"    </a>",
"    ]. Second degree block detected in utero can progress to complete heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/11,32\">",
"     11,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 127 pregnant women with",
"    <span class=\"nowrap\">",
"     anti-SSA/Ro",
"    </span>",
"    antibodies monitored with periodic fetal echocardiograms (weekly from 16 to 26 weeks gestation and biweekly from 26 to 34 weeks), advanced block and cardiomyopathy could occur within 1 week of a normal echocardiogram without initial first-degree block [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/33\">",
"     33",
"    </a>",
"    ]. Moreover, it could occur before 24 weeks of gestation. The authors suggest that it is appropriate to perform intense monitoring between 16 and 24 weeks.",
"   </p>",
"   <p>",
"    Infants who present with heart block in utero, but who survive until birth, have a high neonatal mortality rate. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Long-term prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Presentation in the neonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in the fetus, the cardinal presenting finding in CHB in the neonate is a slow heart rate. In addition to bradycardia, other clinical clues in the neonate include intermittent cannon waves in the neck, a first heart sound that varies in intensity, and intermittent gallops and murmurs. As with cases presenting in utero, almost all presenting in the neonatal period (90 percent in one series) are due to neonatal lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The newborn at greatest risk has a rapid atrial rate, often 150",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    or faster, and a ventricular rate less than 50",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    Similar to acquired CHB, the ECG in congenital CHB most commonly shows a narrow QRS complex due to a junctional or atrioventricular (AV) nodal escape or ectopic rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    .) First or second degree AV block found in infants at birth can progress to CHB [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/11,32\">",
"     11,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome for patients diagnosed as neonates is better than for those diagnosed in utero. In the above cited review, 33 patients presented in the perinatal period; five had signs of heart failure, but none had hydrops fetalis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. None died within the first six months, but two died at 0.9 and 1.5 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Presentation in childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 40 percent of cases of congenital CHB do not present until childhood (mean age five to six years) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. Few of these patients (5 percent) have neonatal lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. The diagnosis is usually made when a slow pulse is detected and heart block is confirmed by ECG or by ambulatory ECG monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6,34,35\">",
"     6,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CHB may be intermittent when first detected, but usually becomes persistent in later childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. It has been suggested that most unexplained CHB diagnosed for the first time beyond infancy is congenital in origin and has escaped notice because of a higher ventricular rate and the absence of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/36\">",
"     36",
"    </a>",
"    ]. However, given that prenatal ultrasound is now a well-developed methodology, it may be that cases currently missed in fetal life have preserved AV conduction at birth and acquire progressive AV nodal disease thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. Consistent with this hypothesis are two observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from one center, the number of childhood case referrals remained constant from 1980 to 1998 despite the introduction of fetal echocardiography and the wide availability of heart rate monitoring during pregnancy and labor [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 102 patients who were asymptomatic through age 15 and were followed for 7 to 30 years thereafter, a slow decline in ventricular rate was noted with increasing age, with a mean heart rate at age 15 of 46 beats per minute and a mean heart rate after age 40 of 39 beats per minute [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients present with bradycardia-related symptoms, including reduced exercise tolerance and presyncope or syncope (Stokes-Adams attacks) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6,34\">",
"     6,34",
"    </a>",
"    ]. Sudden death has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. In the above review of 102 patients who were without symptoms through age 15, 27 (26 percent) had a subsequent syncopal episode, eight of which were fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/35\">",
"     35",
"    </a>",
"    ]. Six of these eight episodes represented a first syncopal episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of congenital CHB in utero and in the perinatal period can include steroid therapy if associated with",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pacemaker insertion immediately after birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link&amp;anchor=H4218950#H4218950\">",
"     \"Neonatal lupus\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principal therapeutic decision after the immediate perinatal period involves the need for pacemaker placement. Most patients ultimately have a pacemaker inserted, regardless of the time of onset of the syndrome. In one study, by 20 years of age, only 11 percent of neonatal and 12 percent of childhood cases had not required pacemaker implantation (",
"    <a class=\"graphic graphic_figure graphicRef55309 \" href=\"UTD.htm?8/55/9086\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ]. Even patients who are free of symptoms at age 15 remain at risk for syncope or sudden cardiac death. In a report of 40 such patients, pacemaker insertion was required in 90 percent by age 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of pacemaker implanted is often based upon clinician preference; either a ventricular (with rate responsiveness) or dual chamber pacemaker can be used. However, most clinicians prefer physiologic dual chamber pacing in young patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of patients with congenital complete heart block are female and survival into childbearing age is anticipated. As noted above, most of these patients will have indications for pacemaker insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic young women with congenital complete heart block and no pacemaker generally experience uneventful pregnancies, provided that the QRS duration is not prolonged (ie, the escape rhythm is junctional and not infranodal) and ventricular function is normal, which is usually the case. However, syncopal episodes occasionally first occur during gestation and the heart and circulation may not respond adequately to the acute circulatory demands of labor and delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LONG-TERM PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CHB presenting in utero or the neonatal period, which is mostly due to neonatal lupus, is associated with a high early mortality. Of 175 cases described in two reports, 29 (17 percent) died either in utero or within the first three months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Survival appears to relate to gestational age at birth, with offspring born before 34 weeks having a higher mortality rate than those born later (52 versus 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/9\">",
"     9",
"    </a>",
"    ]. Infants with first or second degree heart block at birth can progress to complete heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/9,11,32\">",
"     9,11,32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Infants and young children with complete heart block who are asymptomatic usually remain so until later childhood, adolescence, or adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/3,39\">",
"     3,39",
"    </a>",
"    ]. However, exercise limitation and even mortality in childhood are not negligible [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/34,40\">",
"     34,40",
"    </a>",
"    ]. Children with a mean heart rate below 50",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    and evidence of an unstable junctional escape rhythm may be at particular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/34\">",
"     34",
"    </a>",
"    ]. Even patients who have been asymptomatic throughout childhood are at increased risk of sudden death. In a review of 102 patients who were without symptoms through age 15, 27 (26 percent) had a subsequent syncopal episode, eight of which were fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/35\">",
"     35",
"    </a>",
"    ]. Six of these eight episodes represented a first syncopal episode.",
"   </p>",
"   <p>",
"    Those patients who do not experience symptoms or syncopal attacks may still suffer physiologic consequences of bradycardia. The ventricular rate tends to fall slowly with age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/35\">",
"     35",
"    </a>",
"    ]. To compensate for the slow heart rate, the heart enlarges to produce an higher stroke volume; in some cases, this can lead to voltage criteria for left ventricular enlargement and nonspecific ST-T wave changes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/41\">",
"     41",
"    </a>",
"    ] as well as to heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the prognosis following pacemaker implantation is excellent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, it has been suggested that 5 to 11 percent develop heart failure over the long-term, even if a pacemaker is inserted [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. One report evaluated 16 such patients (10 with neonatal lupus) in whom a pacemaker was inserted within the first two weeks of life [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/42\">",
"     42",
"    </a>",
"    ]. Twelve developed heart failure before age 24 months. The major findings on myocardial biopsy were hypertrophy and interstitial fibrosis. During follow-up, four patients died from progressive heart failure and seven required transplantation. In another study of 149 patients followed for 10 years, 6 percent developed a dilated cardiomyopathy by 6.5 years of age; risk factors included",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies, increased heart size at initial evaluation, and the absence of improvement with a pacemaker [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the development of heart failure in such patients may be a consequence of myocardial fibrosis associated with CHB, another factor may be the long term consequences of right ventricular pacing with consequent ventricular asynchrony. This was suggested by a report that compared 23 patients with congenital CHB, each of whom had a pacemaker, to 30 matched healthy control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/46\">",
"     46",
"    </a>",
"    ]. Echocardiography was performed before pacemaker implantation and after at least five years of right ventricular pacing in the CHB patients.",
"   </p>",
"   <p>",
"    The CHB patients with pacemakers developed left ventricular dilatation and asymmetric hypertrophy, asynchronous left ventricular contraction, an increase in left ventricular end-diastolic diameter, a decrease in cardiac output compared to matched controls (3.8 versus 4.9",
"    <span class=\"nowrap\">",
"     L/min),",
"    </span>",
"    and a reduction in exercise performance (123 versus 185 watts). Similar findings have been noted with right ventricular pacing for sick sinus syndrome: a higher cumulative percentage of ventricular paced beats has been associated with a significantly greater incidence of subsequent HF hospitalization and subsequent development of atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10376/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link&amp;anchor=H15#H15\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Pacing modes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=see_link\">",
"       \"Patient information: Heart block in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20369?source=see_link\">",
"       \"Patient information: Heart block in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6036270\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital third degree, or complete, heart block (CHB), a relatively rare disorder affecting between 1 in 15,000 to 1 in 22,000 live-born infants, typically presents as fetal bradycardia with a fetal heart rate of 40 to 80 beats per minute. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal lupus, due to maternal antibodies that cross the placenta, is responsible for 60 to 90 percent of cases of congenital CHB overall. Other causes include myocarditis, various structural cardiac defects (eg, congenitally corrected transposition of the great arteries, atrioventricular discordance, or polysplenia with atrioventricular canal defect), and several hereditary disorders. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal lupus results from transplacental passage of maternal",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-La/SSB",
"      </span>",
"      antibodies. Among women with such antibodies, complete heart block occurs in approximately 2 percent of pregnancies. Once a woman has given birth to an infant with congenital heart block, the recurrence rate of congenital heart block in subsequent pregnancies is about 15 percent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Neonatal lupus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, congenital complete heart block is characterized pathologically by fibrous tissue that either replaces the AV node and its surrounding tissue or by an interruption between the atrial myocardium and the atrioventricular node (AV node). Among infants with CHD due to neonatal lupus,",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-La/SSB",
"      </span>",
"      antibodies bind to fetal cardiac tissue, leading to autoimmune injury of the atrioventricular (AV) node and its surrounding tissue. (See",
"      <a class=\"local\" href=\"#H6036308\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The manifestations of congenital heart block vary with the age at presentation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In utero &mdash; Congenital CHB may present with fetal bradycardia between 18 and 28 weeks of gestation, with the diagnosis being made in most instances using echocardiography. Almost all of these cases (95 percent in one series) are due to neonatal lupus. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Presentation in utero'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the neonate &mdash; In addition to bradycardia, other clinical clues to the presence of CHB in the neonate include intermittent cannon waves in the neck, a first heart sound that varies in intensity, and intermittent gallops and murmurs. As with cases presenting in utero, almost all presenting in the neonatal period (90 percent in one series) are due to neonatal lupus. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Presentation in the neonate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In childhood &mdash; In the up to 40 percent of cases of congenital CHB that do not present until later in childhood (mean age five to six years), the diagnosis is usually made when a slow pulse is detected and heart block is confirmed by ECG or by ambulatory ECG monitoring. CHB may be intermittent when first detected in later childhood but usually becomes persistent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Presentation in childhood'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of congenital CHB in utero and in the perinatal period can include steroid therapy if associated with",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       anti-La/SSB",
"      </span>",
"      antibodies, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pacemaker insertion immediately after birth. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link&amp;anchor=H4218950#H4218950\">",
"       \"Neonatal lupus\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CHB presenting in utero or the neonatal period, which is mostly due to neonatal lupus, is associated with a high early mortality. In general, however, the prognosis following pacemaker implantation is excellent, although patients do appears to be at increased risk of developing heart failure. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Long-term prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733111957\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Peter Zimetbaum, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/1\">",
"      Morquio L. Sur une maladie infantile et familiale characteris&eacute;e par des modifications permanentes du pouls, des attaques syncopales et epileptiforme et la mort subite. Arch M&eacute;d d'Enfants 1901; 4:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/2\">",
"      White P, Eustis R. Congenital heart block. Am J Dis Child 1921; 22:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/3\">",
"      Micha&euml;lsson M, Engle MA. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 1972; 4:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/4\">",
"      Johansen AS, Herlin T. [Neonatal lupus syndrome. Association with complete congenital atrioventricular block]. Ugeskr Laeger 1998; 160:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/5\">",
"      Ross BA. Congenital complete atrioventricular block. Pediatr Clin North Am 1990; 37:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/6\">",
"      Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002; 39:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/7\">",
"      Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/8\">",
"      Buyon JP, Kim MY, Copel JA, Friedman DM. Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient. Arthritis Rheum 2001; 44:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/9\">",
"      Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/10\">",
"      Ho SY, Esscher E, Anderson RH, Micha&euml;lsson M. Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies. Am J Cardiol 1986; 58:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/11\">",
"      Askanase AD, Friedman DM, Copel J, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002; 11:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/12\">",
"      Baruteau AE, Fouchard S, Behaghel A, et al. Characteristics and long-term outcome of non-immune isolated atrioventricular block diagnosed in utero or early childhood: a multicentre study. Eur Heart J 2012; 33:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/13\">",
"      Baruteau AE, Behaghel A, Fouchard S, et al. Parental electrocardiographic screening identifies a high degree of inheritance for congenital and childhood nonimmune isolated atrioventricular block. Circulation 2012; 126:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/14\">",
"      Anderson RH, Wenick AC, Losekoot TG, Becker AE. Congenitally complete heart block. Developmental aspects. Circulation 1977; 56:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/15\">",
"      NAKAMURA FF, NADAS AS. COMPLETE HEART BLOCK IN INFANTS AND CHILDREN. N Engl J Med 1964; 270:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/16\">",
"      ROWE JC, WHITE PD. Complete heart block: a follow-up study. Ann Intern Med 1958; 49:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/17\">",
"      Rosen KM, Mehta A, Rahimtoola SH, Miller RA. Sites of congenital and surgical heart block as defined by His bundle electrocardiography. Circulation 1971; 44:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/18\">",
"      Feldt RH, DuShane JW, Titus JL. The atrioventricular conduction system in persistent common atrioventricular canal defect: correlations with electrocardiogram. Circulation 1970; 42:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/19\">",
"      Lev M, Silverman J, Fitzmaurice FM, et al. Lack of connection between the atria and the more peripheral conduction system in congenital atrioventricular block. Am J Cardiol 1971; 27:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/20\">",
"      Lev M, Cuadros H, Paul MH. Interruption of the atrioventricular bundle with congenital atrioventricular block. Circulation 1971; 43:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/21\">",
"      James TN, Spencer MS, Kloepfer JC. De Subitaneis Mortibus. XXI. Adult onset syncope. with comments on the nature of congenital heart block and the morphogenesis of the human atrioventricular septal junction. Circulation 1976; 54:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/22\">",
"      Reid JM, Coleman EN, Doig W. Complete congenital heart block. Report of 35 cases. Br Heart J 1982; 48:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/23\">",
"      Nasrallah AT, Gillette PC, Mullins CE. Congenital and surgical atrioventricular block within the His bundle. Am J Cardiol 1975; 36:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/24\">",
"      Sholler GF, Walsh EP. Congenital complete heart block in patients without anatomic cardiac defects. Am Heart J 1989; 118:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/25\">",
"      Alexander E, Buyon JP, Provost TT, Guarnieri T. Anti-Ro/SS-A antibodies in the pathophysiology of congenital heart block in neonatal lupus syndrome, an experimental model. In vitro electrophysiologic and immunocytochemical studies. Arthritis Rheum 1992; 35:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/26\">",
"      Miranda-Car&uacute;s ME, Askanase AD, Clancy RM, et al. Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages. J Immunol 2000; 165:5345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/27\">",
"      Garcia S, Nascimento JH, Bonfa E, et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994; 93:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/28\">",
"      Xiao GQ, Hu K, Boutjdir M. Direct inhibition of expressed cardiac l- and t-type calcium channels by igg from mothers whose children have congenital heart block. Circulation 2001; 103:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/29\">",
"      Cruz RB, Viana VS, Nishioka SA, et al. Is isolated congenital heart block associated to neonatal lupus requiring pacemaker a distinct cardiac syndrome? Pacing Clin Electrophysiol 2004; 27:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/30\">",
"      Nield LE, Silverman ED, Taylor GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002; 105:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/31\">",
"      Glickstein JS, Buyon J, Friedman D. Pulsed Doppler echocardiographic assessment of the fetal PR interval. Am J Cardiol 2000; 86:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/32\">",
"      Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/33\">",
"      Friedman DM, Kim MY, Copel JA, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/34\">",
"      Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block. N Engl J Med 1987; 316:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/35\">",
"      Micha&euml;lsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation 1995; 92:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/36\">",
"      Pinsky WW, Gillette PC, Garson A Jr, McNamara DG. Diagnosis, management, and long-term results of patients with congenital complete atrioventricular block. Pediatrics 1982; 69:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/37\">",
"      Karpawich PP, Gillette PC, Garson A Jr, et al. Congenital complete atrioventricular block: clinical and electrophysiologic predictors of need for pacemaker insertion. Am J Cardiol 1981; 48:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/38\">",
"      Esscher EB. Congenital complete heart block in adolescence and adult life. A follow-up study. Eur Heart J 1981; 2:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/39\">",
"      McHenry MM. Factors influencing longevity in adults with congenital complete heart block. Am J Cardiol 1972; 29:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/40\">",
"      Reybrouck T, Vanden Eynde B, Dumoulin M, Van der Hauwaert LG. Cardiorespiratory response to exercise in congenital complete atrioventricular block. Am J Cardiol 1989; 64:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/41\">",
"      Kertesz NJ, Friedman RA, Colan SD, et al. Left ventricular mechanics and geometry in patients with congenital complete atrioventricular block. Circulation 1997; 96:3430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/42\">",
"      Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001; 37:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/43\">",
"      Udink ten Cate FE, Breur JM, Cohen MI, et al. Dilated cardiomyopathy in isolated congenital complete atrioventricular block: early and long-term risk in children. J Am Coll Cardiol 2001; 37:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/44\">",
"      Pordon CM, Moodie DS. Adults with congenital complete heart block: 25-year follow-up. Cleve Clin J Med 1992; 59:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/45\">",
"      Groves AM, Allan LD, Rosenthal E. Outcome of isolated congenital complete heart block diagnosed in utero. Heart 1996; 75:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/46\">",
"      Thambo JB, Bordachar P, Garrigue S, et al. Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 2004; 110:3766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10376/abstract/47\">",
"      Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003; 107:2932.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 912 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10376=[""].join("\n");
var outline_f10_8_10376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6036270\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18519160\">",
"      Non-immune congenital AV block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6036308\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Presentation in utero",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Presentation in the neonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Presentation in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LONG-TERM PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6036270\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H733111957\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/912\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/912|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/55/9086\" title=\"figure 1\">",
"      Pacemaker congenital CHB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/26/44449?source=related_link\">",
"      Patient information: Heart block in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20369?source=related_link\">",
"      Patient information: Heart block in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_8_10377="Suicidal ideation and behavior in adults";
var content_f10_8_10377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Suicidal ideation and behavior in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10377/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10377/contributors\">",
"     Jennifer Schreiber, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10377/contributors\">",
"     Larry Culpepper, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10377/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10377/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10377/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10377/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/8/10377/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each year, about 30,000 people in the United States and one million worldwide die by suicide; 650,000 people in the United States receive emergency treatment each year after attempting suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary care providers may be in a unique position due to their frequency of interaction with suicidal patients. A review of 40 studies found that over 75 percent of patients who committed suicide had contact with primary care providers within the year of their death, compared with one-third who had contact with mental health services [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/2\">",
"     2",
"    </a>",
"    ]. Similarly, twice as many suicide victims had contact with primary care providers as mental health services in the month before their suicide (45 versus 20 percent).",
"   </p>",
"   <p>",
"    Despite this, there are no data to show that screening for suicide in primary care reduces mortality. Additionally, predicting which patients with suicidal thoughts will go on to attempt suicide cannot be achieved with a high degree of sensitivity or specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, the fact that primary care clinicians see a large portion of the patients who subsequently commit suicide suggests that an approach to case finding based on risk factors a sensitivity to high-risk situations in depressed patients, and clear documentation that suicidality was assessed in patients being treated for depression are appropriate in the primary care setting, and may uncover occasional patients who make their intent known and are amenable to intervention.",
"   </p>",
"   <p>",
"    This topic reviews risk factors for suicide, and the evaluation, initial management, and appropriate follow-up of the suicidal patient. A discussion of suicidality related to use of antidepressants is presented separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suicidal ideation and behavior are among the most serious and common psychiatric emergencies. Reported rates of suicide, however, may underestimate the true burden because of misclassification of death due to legal or social stigma and procedural issues related to death registration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suicide is the tenth leading cause of death worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/5\">",
"     5",
"    </a>",
"    ] and accounted for 1.2 percent of all deaths in the United States in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The 2004 suicide rate in the United States, based on data reported from seven states, was 10.6 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/8\">",
"     8",
"    </a>",
"    ], a significant decrease from 12.4 per 100,000 in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/9\">",
"     9",
"    </a>",
"    ]. Suicide rates also declined in England and Wales, with suicide rates for young men at their highest level in 1998 and at their lowest level in 2005, lower than they had been in the previous 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/10\">",
"     10",
"    </a>",
"    ]. Suicide rates, however, are greater in China, former Soviet states, and other developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2004 US suicide rate for men was four times higher than the rate for women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/8\">",
"     8",
"    </a>",
"    ]. The highest rate (28.9 per 100,000) was found in males &ge;65 years of age.",
"   </p>",
"   <p>",
"    It is estimated that there are 10 to 40 nonfatal suicide attempts for every completed suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]. This number increases to 100 to 200 for adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of suicidal thoughts, plans, gestures, and attempts does not appear to have changed significantly in the US between the early 1990s and the early 2000s [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/13\">",
"     13",
"    </a>",
"    ]. In 2004, 19 percent of suicide victims had a history of prior attempts; 16.5 percent had alcohol-related problems [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of suicides completed in the United States are accomplished with firearms (57 percent overall, 62 percent of suicides in men) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/7\">",
"     7",
"    </a>",
"    ]. Suicide rates are increased 4 to 10 times in adolescents who live in a household with a gun. The second leading method of suicide in the United States is hanging for men and poisoning for women. In many developing countries, pesticide ingestion is responsible for the majority of suicide deaths and may account for 30 percent of suicides globally [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors are associated with an increased risk of suicide:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric illness is a strong predictor of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. More than 90 percent of patients who attempt suicide have a major psychiatric disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/7,11\">",
"     7,11",
"    </a>",
"    ], and 95 percent of patients who successfully commit suicide have a psychiatric diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with psychiatric diagnoses kill themselves at rates 3 to 12 times higher than other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severity of psychiatric illness is associated with risk of suicide. As an example, a meta-analysis found that the lifetime risk of suicide is 8.6 percent in patients who have had a psychiatric inpatient admission involving suicidal ideation, 4 percent in patients who have had a psychiatric admission for an affective disorder without suicidality, 2.2 percent in psychiatric outpatients, and less than 0.5 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients who have multiple psychiatric comorbidities appear to be at higher risk than those with uncomplicated depression or an anxiety disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suicide may be concentrated in the days and weeks following psychiatric inpatient hospitalization. In one systematic review, 41 percent of those who committed suicide had been psychiatric inpatients within the previous year and as many as 9 percent of suicides occurred within one day of discharge from psychiatric inpatient care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/20\">",
"     20",
"    </a>",
"    ]. This last figure may have been inflated by including some patients who committed suicide during their inpatient stays.",
"   </p>",
"   <p>",
"    The most common associated psychiatric disorders include depression, bipolar disorder, alcoholism or other substance abuse, schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/21\">",
"     21",
"    </a>",
"    ], personality disorders, anxiety disorders including panic disorder, posttraumatic stress disorders, and delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/22\">",
"     22",
"    </a>",
"    ]. Among patients with depression, a history of suicide attempts correlated most strongly with feelings of worthlessness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/23\">",
"     23",
"    </a>",
"    ]. Concurrent personality disorder was also strongly correlated with suicide attempts in depressed patients.",
"   </p>",
"   <p>",
"    Anxiety disorders more than double the risk of suicide attempts (OR 2.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/24\">",
"     24",
"    </a>",
"    ] and a combination of depression and anxiety greatly increases the risk (OR 17) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/22\">",
"     22",
"    </a>",
"    ]. Symptoms of psychosis (delusions, command auditory hallucinations, paranoia) may increase the risk regardless of diagnosis.",
"   </p>",
"   <p>",
"    The reported rate of suicide among alcoholics has ranged from 2 to 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Almost 90 percent of alcoholic suicides are committed by men. Of people who commit suicide, approximately 20 to 25 percent are intoxicated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1\">",
"     1",
"    </a>",
"    ]. In a CDC study from 13 states, alcohol was detected in 33.3 percent of suicide victims tested for substance abuse in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/27\">",
"     27",
"    </a>",
"    ]. In that same report, 16.4 percent tested positive for opiates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hopelessness and impulsivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Across psychiatric disorders, hopelessness is strongly associated with suicide. As an example, in one multivariate model, hopelessness was 1.3 times more important than depression in explaining suicidal ideation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/28\">",
"     28",
"    </a>",
"    ]. Hopelessness can persist even when other symptoms of depression have remitted [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/29\">",
"     29",
"    </a>",
"    ]. Hopelessness may mediate the relationship between low self esteem, loneliness, interpersonal losses, and suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impulsivity, particularly among adolescents and young adults, is also associated with acting on suicidal thoughts, and the combination of hopelessness, impulsivity, and disinhibition from substance abuse may be particularly lethal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History of previous suicide attempts or threats",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strongest single factor predictive of suicide is prior history of attempted suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with a prior history of suicide attempts are 5 to 6 times more likely to make another attempt; furthermore, up to 50 percent of successful victims have made a prior attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/32\">",
"     32",
"    </a>",
"    ]. One of every 100 suicide attempt survivors will die by suicide within one year of their index attempt, a risk approximately 100 times that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk for completed suicide, following a history of suicide attempt, is greatest in patients with schizophrenia or unipolar and bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Age, sex, and race",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of suicide increases with increasing age, however young adults attempt suicide more often than older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Females attempt suicide four times more frequently than males, but males are successful three times more often [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/37\">",
"     37",
"    </a>",
"    ]. These age and sex differences appear to be primarily related to the lethality of the method chosen (eg, firearms, hanging, jumping, etc.) rather than a difference in completion rates for the same method [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elderly white men, aged 85 years and older, have the highest suicide rate",
"    <span class=\"nowrap\">",
"     (51.6/year",
"    </span>",
"    per 100,000 population) in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/39\">",
"     39",
"    </a>",
"    ]. Although suicide rates have been higher among whites than blacks (12 compared to 5 per 100,000 in 2003) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/39\">",
"     39",
"    </a>",
"    ], the rate differences between races have been narrowing in recent years, with increasing rates of suicide attempts especially among young black males [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Marital status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suicide risk varies with marital status [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/41\">",
"     41",
"    </a>",
"    ]. The highest risk occurs among those never married, followed in descending order of risk by widowed, separated, or divorced; married without children; and married with children. Whatever the family structure, living alone increases the risk of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Occupation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unemployed and unskilled patients are at higher risk for suicide than those who are employed and skilled; a recent sense of failure may lead to higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians may be at increased risk of suicide. A meta-analysis of 25 studies found a suicide rate ratio for male clinicians of 1.41 (95% CI 1.21-1.65) and for female clinicians of 2.27 (95% CI 1.90-2.73) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suicide risk increases with physical illness such as chronic pain, recent surgery, and chronic or terminal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. HIV infection alone does not appear to increase risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/48\">",
"     48",
"    </a>",
"    ]. BMI and risk of suicide are inversely related in men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adverse childhood experiences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood abuse and other adverse childhood experiences appear to increase the risk of suicide in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. As an example, a retrospective cohort study found a graded relationship between the number of adverse childhood experiences (defined as emotional abuse, physical abuse, sexual abuse, battered mother, substance abuse in home, mentally ill household member, parents",
"    <span class=\"nowrap\">",
"     separated/divorced,",
"    </span>",
"    and incarcerated family member) and suicide risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/51\">",
"     51",
"    </a>",
"    ]. This relationship appeared to be at least partially mediated by the presence of alcoholism, depression, and illicit drug use, which are also strongly associated with adverse events in childhood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Family history and genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of suicide increases in patients with a family history of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Having a first-degree relative who committed suicide increases the risk six-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1\">",
"     1",
"    </a>",
"    ]. Twin studies suggest that this increased risk has both environmental and genetic components [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. The heritability of suicide is in the range of 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1\">",
"     1",
"    </a>",
"    ]. However, it is not clear whether the genetic component is primarily responsible for the underlying psychiatric disorder or for the suicide itself. In one study, both a family history of completed suicide and psychiatric illness were risk factors for suicide, and the effect of family suicide history was independent of the family history of psychiatric illness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/53\">",
"     53",
"    </a>",
"    ]. Additionally, having an unrelated spouse who has a psychiatric disorder or who commits suicide increases the risk of suicide, showing the importance of environmental effects within the family structure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential association of antidepressant therapy in adults with an increased risk of suicide is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of suicide increases in patients with accessibility to weapons, especially firearms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/56\">",
"     56",
"    </a>",
"    ]. Risk also increases in patients who live alone, have lost a loved one, or have experienced a failed relationship within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/57\">",
"     57",
"    </a>",
"    ]; and possibly in patients with a history of violent behavior in the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/58\">",
"     58",
"    </a>",
"    ]. The anniversary of a significant relationship loss is also a time of increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/59\">",
"     59",
"    </a>",
"    ]. Among those widowed, the risk of suicide is highest in the first week after bereavement, decreasing rapidly in the first months thereafter, but remaining elevated throughout the first year following the loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sociopolitical, cultural, and economic forces can lead to increased suicide rates in populations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1,61\">",
"     1,61",
"    </a>",
"    ]. Violence and political coercion are associated with increased rates of suicide, as are economic downturns. Those living in rural areas have higher rates of suicide than those living in urban areas. In a survey of adolescents, those who identified themselves as lesbian, gay, or bisexual reported higher rates of suicidal ideation and suicide attempts than heterosexual respondents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/62\">",
"     62",
"    </a>",
"    ]. People who score lower on intelligence tests also appear to have a higher risk of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROTECTIVE FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social support and family connectedness is protective against suicide, while family discord increases the risk of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1\">",
"     1",
"    </a>",
"    ]. Pregnancy decreases the risk of suicide, as does parenthood [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/64\">",
"     64",
"    </a>",
"    ], particularly for mothers. Religiosity and participating in religious activities is associated with a lower risk of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians worry at times that asking about suicide will initiate suicidal thoughts or actions, but there are no data to support this concern. In contrast, many patients appreciate the opportunity to discuss suicidal thoughts, and may not verbalize these issues without being prompted. Sometimes the only clue to a suicidal patient is the initiation of an office visit.",
"   </p>",
"   <p>",
"    The observation that patients who subsequently commit suicide have often recently visited primary care clinicians has been interpreted as reflecting help-seeking behavior. However, clinicians may be unaware of their patient's intent. As an example, in one study of depressed suicide victims, 59 percent cared for in a psychiatric setting had communicated their intent compared with only 19 percent cared for in a medical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/66\">",
"     66",
"    </a>",
"    ]. While patients may be reluctant to communicate their intent to commit suicide, patients with suicidal ideation will generally tell their clinicians about such thoughts when asked [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of a patient who may be suicidal includes an assessment of ideation, plan, and intent. Unfortunately, our ability to predict who will attempt suicide is limited; patients who commit suicide are similar to those who do not [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/68\">",
"     68",
"    </a>",
"    ]. As an example, one study of 4800 psychiatric inpatients who were evaluated using the risk factors described above found that trying to identify particular people who would or would not commit suicide was not feasible because of the low sensitivity and specificity of available identification procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/32\">",
"     32",
"    </a>",
"    ]. Similarly, among patients who have presented to an emergency department after an episode of self-harm, assessments by psychiatrists and emergency department staff have low sensitivity and specificity for predicting who will repeat self-harm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of standardized scales have been proposed to evaluate suicide risk, but none is associated with a high predictive value. Depression rating scales are commonly used, but these are better measures of depression severity than suicide risk. The Beck Hopelessness Scale is a 20 item",
"    <span class=\"nowrap\">",
"     true/false",
"    </span>",
"    questionnaire that correlates more closely with current suicide attempt than does depression. (Available for purchase",
"    <a class=\"external\" href=\"file://www.pearsonassessments.com/HAIWEB/Cultures/en-us/Productdetail.htm?Pid=015-8133-609&amp;Mode=summary\">",
"     online",
"    </a>",
"    ). However, a meta-analysis found that the low specificity of the Beck scale limits its applicability in clinical practice to identify and intervene in patients with high risk for suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Suicidal ideation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in evaluating suicide risk is to determine the presence of suicidal thoughts, including their content and duration. If present, the clinician should ask about changes in what may be chronic thoughts (eg, increased intensity or frequency), and if or how the patient has been controlling these thoughts. The questioning can be performed in a variety of ways, ranging from asking if the patient has lost interest in living or feels at times that he or she would be better off dead, to directly asking if the patient has thought of ending his or her own life. Other inquiries include the patient's expectations about death (including thoughts of reuniting with lost significant others), thoughts of evoking punishment of others, the need to escape a painful physical or psychological situation, or thoughts of harming others first before harming him or herself.",
"   </p>",
"   <p>",
"    The presence of a suicide plan and intent can be elicited by asking about the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Has a plan been formulated or implemented, including a specific method, place, and time? What is the anticipated outcome of the plan?",
"     </li>",
"     <li>",
"      Are the means of committing suicide available or readily accessible? Does the patient know how to use these means?",
"     </li>",
"     <li>",
"      What is the lethality of the plan? What is the patient's conception of lethality versus the objective lethality?",
"     </li>",
"     <li>",
"      What is the likelihood of rescue?",
"     </li>",
"     <li>",
"      Have any preparations been made (eg, gathering pills, changing wills, suicide notes) or how close has the patient come to completing the plan? Has the patient practiced the suicidal act or has an actual attempt already been made?",
"     </li>",
"     <li>",
"      What is the strength of the intent to carry out suicidal thoughts and plans, including the ability to control impulsivity?",
"     </li>",
"     <li>",
"      What is the accessibility of support systems and recent stressors that may threaten the patient's ability to cope with difficulties and ability to participate in treatment planning?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be assessed for hopelessness and their view of the future. Also, ask about alcohol and substance abuse history, and whether there is a history of binging.",
"   </p>",
"   <p>",
"    Observe whether the patient shows disconnectedness or a lack of rapport during the clinical interview, since these increase the risk of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the suicidal individual should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reducing immediate risk",
"     </li>",
"     <li>",
"      Managing underlying factors",
"     </li>",
"     <li>",
"      Monitoring and follow-up",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reducing immediate risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate psychiatric services, usually including hospitalization, are necessary in patients felt to be at imminent risk for self-harm. Attempts should be made to contact the patient's mental health provider if one exists.",
"   </p>",
"   <p>",
"    The highest priority is to assure the patient's safety, which may necessitate having a staff member sit with the patient while arrangements for further care are made. The room should be cleared of objects that could potentially be used to inflict harm. The patient's belongings also may need to be searched since potential methods for self-harm may be easily accessible. If the patient demands to leave, security staff or local police may need to be called to detain or bring him or her to an emergency department for further evaluation.",
"   </p>",
"   <p>",
"    Patients need to be transported to the appropriate facility via ambulance; they should not be sent alone or even with family.",
"   </p>",
"   <p>",
"    Patients in whom the risk of suicide is high but not imminent (eg, those with depression or alcohol abuse who express a desire to commit suicide but who do not have a specific plan) need aggressive treatment, but not necessarily hospitalization. Useful measures in these individuals include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Involve a family member or person close to the patient, if allowed.",
"     </li>",
"     <li>",
"      Ask about the availability of lethal means (eg, firearms, medications) and make them inaccessible to the patient.",
"     </li>",
"     <li>",
"      Increase the frequency of contact with the patient; communicate a commitment to help.",
"     </li>",
"     <li>",
"      Begin aggressive treatment of psychiatric disorders or substance abuse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Older antidepressant medications such as tricyclic antidepressants and monoamine oxidase inhibitors may be lethal if taken in high doses; they should be avoided if possible in the depressed patient who has expressed thoughts of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    .) The selective serotonin reuptake inhibitors (SSRIs) appear to be much safer when taken in overdose and should be the drugs of choice in potentially suicidal depressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/73\">",
"     73",
"    </a>",
"    ]. The serotonin norepinephrine reuptake inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    may be dangerous in overdose and should probably be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For severely depressed suicidal patients, the rapid onset of effect of ECT may be lifesaving, at least in the short term; long-term effectiveness has yet to be demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Contracting for safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;As part of assessing or supporting a patient's ability to avoid acting on suicidal thoughts, the concept of \"contracting for safety\" or agreeing to a \"no harm contract\" has been used in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/75\">",
"     75",
"    </a>",
"    ]. The terms imply that patients can promise clinicians that they will try not to harm themselves when they are suicidal. The terms are not consistently defined or used, and clinicians generally do not receive formal training in suicide prevention contracts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/76\">",
"     76",
"    </a>",
"    ]. Additionally, despite their wide use in clinical practice, there is little evidence that such contracts actually reduce suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1\">",
"     1",
"    </a>",
"    ]. As such, contracts may provide a false sense of security. Better tools include open dialogue between patients and clinicians to establish a therapeutic alliance and the performance of ongoing comprehensive assessments of suicide risk over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Managing underlying factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once immediate safety has been ensured, underlying factors should be addressed including precipitating events, ongoing life difficulties, and mental disorders.",
"   </p>",
"   <p>",
"    Precipitating events include such things as the death of a loved one, loss of a job, breakup of a marriage, school or social failure, sexual identity crisis, or trauma. A person may attempt suicide as an alternative to intolerable life circumstances, such as abusive relationships, occupational stresses, and chronic isolation. Referral for counseling is indicated, and engagement of community, religious, and family supports may be helpful if available.",
"   </p>",
"   <p>",
"    Cognitive behavioral therapy (CBT) may be an effective intervention in secondary prevention of suicide attempts in adults. A randomized controlled study of patients seen in an emergency department following suicide attempt (n = 120) showed a significant reduction in suicide attempts over 18 months for patients who received short term CBT compared to usual care (24.1 versus 41.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the majority of suicidal patients, there is an underlying inadequately treated mental disorder. Psychologic autopsy studies demonstrate that only 8 to 17 percent of all suicides were under treatment with psychiatric medications and only 6 to 14 percent of depressed suicide victims were being adequately treated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of depression with antidepressants appears to decrease overall rates of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/1,78,79\">",
"     1,78,79",
"    </a>",
"    ]. As an example, in Sweden a doubling of SSRI prescriptions was associated with a 25 percent reduction in suicides [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/80\">",
"     80",
"    </a>",
"    ]. However, it is important to realize that some patients may respond to antidepressant treatment with improvement in depression without an initial decrease in suicidality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/29\">",
"     29",
"    </a>",
"    ]. Concerns have been raised about increased suicidality in some patients after initiation of antidepressant therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with bipolar disorder,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    has been consistently demonstrated to reduce the rate of suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary care providers should work to ensure that patients remain in appropriate psychiatric treatment. Patients discharged from psychiatric inpatient care are at high short-term risk, particularly if there is a break in the continuity of care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Monitoring and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients identified as at risk of suicide should be followed regularly. Suicide risk fluctuates and should be reassessed frequently, particularly if the patient's situation changes. As part of monitoring previously suicidal patients, the clinician should determine if there have been changes, especially a reemergence of precipitating events, adverse life circumstances, or mental disorders. Following acute management, the primary care provider should assure that previously suicidal patients are actively engaged in ongoing care for any mental disorders and that they continue to receive treatment for prevention of relapse or recurrence of depression, bipolar disorder, anxiety disorders, psychosis, or other conditions. For those with a history of alcohol or substance abuse, monitoring and assisting the patient in remaining in programs that promote adequate control can be critical.",
"   </p>",
"   <p>",
"    The days and initial weeks following discharge from psychiatric hospitalization are a time of increased risk, particularly if patients perceive that they have lost a therapeutic support system, including contact with a primary mental health professional. This is also a time at which patients are at high risk for nonadherence to medication regimens and thus have a consequent increased risk of suicide. Such nonadherence may be due to side effects, lack of symptom relief, lack of understanding, or failure to appreciate the consequences. In contrast, those who continue care in the community and who maintain pharmacotherapy are at lower risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     POST SUICIDE INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post suicide interventions are designed to help family, friends, or coworkers after a suicide. They seek to help those involved understand why the suicide victim killed him or herself, and decrease the assumption of inappropriate guilt for the person's death. Often, the intervention is designed to identify those at risk of suicide either as a response to or in imitation of the original suicide.",
"   </p>",
"   <p>",
"    There is little research on the effectiveness of such interventions in preventing further suicides. Some survivors may be at risk of developing posttraumatic stress disorder (PTSD) or depression. Single session interventions after a traumatic event (\"debriefing\") do not appear to be helpful in preventing PTSD and may actually be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. Monitoring for such conditions and for progress through an adequate process of grieving may, however, be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine screening of adults in a primary care population for suicidal ideation has not been proven to be of benefit. The US Preventive Services Task Force (USPSTF) concluded that there is insufficient evidence to recommend for or against routine screening [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/87\">",
"     87",
"    </a>",
"    ]. The USPSTF clinical practice guideline for screening for suicide risk, as well as other USPSTF guidelines, can be accessed through the website for the Agency for Healthcare Research and Quality at",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     www.ahrq.gov/clinic/uspstfix.htm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Similarly, the Canadian Task Force on Preventive Health Care found poor evidence to recommend for or against routine evaluation of suicide risk even in individuals at high risk for suicide but recommends screening of high-risk individuals given the high burden of suffering [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10377/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major risk factors for suicide include psychiatric disorders, hopelessness, and prior suicide attempts or threats. High impulsivity and alcohol or other substance abuse increases the risk that suicidal impulses will be carried out. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=see_link\">",
"       \"Effect of antidepressants on suicide risk in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients suspected to be at risk for suicide should be asked about suicidal ideation and intent, and, if present, the lethality of the plan should be evaluated. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Patient evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients at imminent risk for suicide require immediate psychiatric services and must be monitored continuously until they are in a safe situation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After immediate safety has been ensured, underlying factors of psychiatric disorders, precipitating events, and ongoing life circumstances should be addressed with medications, counseling, and involvement of friends, family, and",
"      <span class=\"nowrap\">",
"       religious/community",
"      </span>",
"      groups as appropriate. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Managing underlying factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients are at increased risk for suicide soon after discharge from psychiatric inpatient care. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Monitoring and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a history of suicidality should be monitored closely in follow-up and assessed for the recurrence of symptoms or risk factors. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Monitoring and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After a suicide, friends, family, and coworkers may be at increased risk for suicide and for posttraumatic stress disorder and depression, and may benefit from monitoring for appropriate grieving. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Post suicide intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Reducing suicide: A national imperative. Goldsmith, SK, Pellmar, TC, Kleinman, AM, Bunney, WE (Eds). Institute of Medicine National Academies Press, Washington 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/2\">",
"      Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide: a review of the evidence. Am J Psychiatry 2002; 159:909.",
"     </a>",
"    </li>",
"    <li>",
"     Hyman, SE. The suicidal patient. In: Manual of Psychiatric Emergencies, 3rd Ed, Hyman, SE, Tesar, GE, (Eds), Little, Brown, Boston, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/4\">",
"      Sher L. Preventing suicide. QJM 2004; 97:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/5\">",
"      Hawton K, van Heeringen K. Suicide. Lancet 2009; 373:1372.",
"     </a>",
"    </li>",
"    <li>",
"     McIntosh, JL. USA suicide 1999. Official final data. American Association of Suicidology, Washington, DC, 2001.",
"    </li>",
"    <li>",
"     Moscicki, E. Epidemiology of suicide. In: Goldsmith, S, ed, Suicide prevention and intervention, National Academy Press, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Homicides and suicides--National Violent Death Reporting System, United States, 2003-2004. MMWR Morb Mortal Wkly Rep 2006; 55:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Homicide and suicide rates--national violent death reporting system, six states, 2003. MMWR Morb Mortal Wkly Rep 2005; 54:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/10\">",
"      Biddle L, Brock A, Brookes ST, Gunnell D. Suicide rates in young men in England and Wales in the 21st century: time trend study. BMJ 2008; 336:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/11\">",
"      Hirschfeld RM, Russell JM. Assessment and treatment of suicidal patients. N Engl J Med 1997; 337:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/12\">",
"      Haukka J, Suominen K, Partonen T, L&ouml;nnqvist J. Determinants and outcomes of serious attempted suicide: a nationwide study in Finland, 1996-2003. Am J Epidemiol 2008; 167:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/13\">",
"      Kessler RC, Berglund P, Borges G, et al. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003. JAMA 2005; 293:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/14\">",
"      Tidemalm D, L&aring;ngstr&ouml;m N, Lichtenstein P, Runeson B. Risk of suicide after suicide attempt according to coexisting psychiatric disorder: Swedish cohort study with long term follow-up. BMJ 2008; 337:a2205.",
"     </a>",
"    </li>",
"    <li>",
"     Litman, RE. Suicides: What do they have in mind? In: Suicide: Understanding and Responding. Jacobs, D, Brown, HN (Eds), International Universities Press, Madison 1989. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/16\">",
"      Evenson RC, Wood JB, Nuttall EA, Cho DW. Suicide rates among public mental health patients. Acta Psychiatr Scand 1982; 66:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/17\">",
"      Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000; 157:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/18\">",
"      Keller MB, Hanks DL. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995; 56 Suppl 6:22.",
"     </a>",
"    </li>",
"    <li>",
"     Lonnqvist, JK. Psychiatric aspects of suicidal behavior: depression. In: The International Handbook of Suicide and Attempted Suicide, Hawton, K, Heeringen, KV (Eds), Wiley, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/20\">",
"      Pirkis J, Burgess P. Suicide and recency of health care contacts. A systematic review. Br J Psychiatry 1998; 173:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/21\">",
"      Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005; 62:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/22\">",
"      Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005; 62:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/23\">",
"      Bolton JM, Belik SL, Enns MW, et al. Exploring the correlates of suicide attempts among individuals with major depressive disorder: findings from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2008; 69:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/24\">",
"      Bolton JM, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicide attempts: findings from the Baltimore Epidemiologic Catchment area follow-up study. Depress Anxiety 2008; 25:477.",
"     </a>",
"    </li>",
"    <li>",
"     Roy, A, Linnoila, M. Alcoholism and suicide. In: Biology of Suicide, Maris, RW, Guilford, New York 1986.",
"    </li>",
"    <li>",
"     Murphy, GE. Suicide in alcoholism. Oxford, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Toxicology testing and results for suicide victims--13 states, 2004. MMWR Morb Mortal Wkly Rep 2006; 55:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/28\">",
"      Beck AT, Steer RA, Beck JS, Newman CF. Hopelessness, depression, suicidal ideation, and clinical diagnosis of depression. Suicide Life Threat Behav 1993; 23:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/29\">",
"      Szanto K, Reynolds CF 3rd, Conwell Y, et al. High levels of hopelessness persist in geriatric patients with remitted depression and a history of attempted suicide. J Am Geriatr Soc 1998; 46:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/30\">",
"      Dieserud G, R&oslash;ysamb E, Ekeberg O, Kraft P. Toward an integrative model of suicide attempt: a cognitive psychological approach. Suicide Life Threat Behav 2001; 31:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/31\">",
"      Welte JW, Abel EL, Wieczorek W. The role of alcohol in suicides in Erie County, NY, 1972-84. Public Health Rep 1988; 103:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/32\">",
"      Pokorny AD. Prediction of suicide in psychiatric patients. Report of a prospective study. Arch Gen Psychiatry 1983; 40:249.",
"     </a>",
"    </li>",
"    <li>",
"     Hawton, K. Suicide and attempted suicide. In: Handbook of Affective Disorders, 2nd ed, Pankel, ES (Ed), Guilford, New York 1992. p.635.",
"    </li>",
"    <li>",
"     Dorward, RA, Chartock, L. Suicide: A public health perspective. In: Suicide: Understanding and Responding. Jacobs, D, Brown, HN (Eds), International Universities Press, Madison 1989. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/35\">",
"      Spicer RS, Miller TR. Suicide acts in 8 states: incidence and case fatality rates by demographics and method. Am J Public Health 2000; 90:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/36\">",
"      O'Connell H, Chin AV, Cunningham C, Lawlor BA. Recent developments: suicide in older people. BMJ 2004; 329:895.",
"     </a>",
"    </li>",
"    <li>",
"     Psychiatric Emergencies. In: Kaplan and Sadock. Synopsis of Psychiatry, 7th ed, Kaplan, HI, Sadock, BJ, Grebb, JA (Eds), Williams &amp; Wilkins, Baltimore 1994. p.803.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/38\">",
"      Miller M, Azrael D, Hemenway D. The epidemiology of case fatality rates for suicide in the northeast. Ann Emerg Med 2004; 43:723.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Web-based injury statistics query and reporting system. www.cdc.gov/ncipc/wisqars. Accessed November 2, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/40\">",
"      Joe S, Baser RE, Breeden G, et al. Prevalence of and risk factors for lifetime suicide attempts among blacks in the United States. JAMA 2006; 296:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/41\">",
"      Monk M. Epidemiology of suicide. Epidemiol Rev 1987; 9:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/42\">",
"      Heikkinen ME, Isomets&auml; ET, Marttunen MJ, et al. Social factors in suicide. Br J Psychiatry 1995; 167:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/43\">",
"      Platt S. Unemployment and suicidal behaviour: a review of the literature. Soc Sci Med 1984; 19:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/44\">",
"      Stack S. Suicide: a 15-year review of the sociological literature. Part I: cultural and economic factors. Suicide Life Threat Behav 2000; 30:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/45\">",
"      Schernhammer ES, Colditz GA. Suicide rates among physicians: a quantitative and gender assessment (meta-analysis). Am J Psychiatry 2004; 161:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/46\">",
"      Kontaxakis VP, Christodoulou GN, Mavreas VG, Havaki-Kontaxaki BJ. Attempted suicide in psychiatric outpatients with concurrent physical illness. Psychother Psychosom 1988; 50:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/47\">",
"      Juurlink DN, Herrmann N, Szalai JP, et al. Medical illness and the risk of suicide in the elderly. Arch Intern Med 2004; 164:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/48\">",
"      Dannenberg AL, McNeil JG, Brundage JF, Brookmeyer R. Suicide and HIV infection. Mortality follow-up of 4147 HIV-seropositive military service applicants. JAMA 1996; 276:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/49\">",
"      Mukamal KJ, Kawachi I, Miller M, Rimm EB. Body mass index and risk of suicide among men. Arch Intern Med 2007; 167:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/50\">",
"      Brodsky BS, Oquendo M, Ellis SP, et al. The relationship of childhood abuse to impulsivity and suicidal behavior in adults with major depression. Am J Psychiatry 2001; 158:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/51\">",
"      Dube SR, Anda RF, Felitti VJ, et al. Childhood abuse, household dysfunction, and the risk of attempted suicide throughout the life span: findings from the Adverse Childhood Experiences Study. JAMA 2001; 286:3089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/52\">",
"      Egeland JA, Sussex JN. Suicide and family loading for affective disorders. JAMA 1985; 254:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/53\">",
"      Qin P, Agerbo E, Mortensen PB. Suicide risk in relation to family history of completed suicide and psychiatric disorders: a nested case-control study based on longitudinal registers. Lancet 2002; 360:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/54\">",
"      Roy A, Segal NL, Centerwall BS, Robinette CD. Suicide in twins. Arch Gen Psychiatry 1991; 48:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/55\">",
"      Agerbo E. Risk of suicide and spouse's psychiatric illness or suicide: nested case-control study. BMJ 2003; 327:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/56\">",
"      Helmkamp JC. Occupation and suicide among males in the US Armed Forces. Ann Epidemiol 1996; 6:83.",
"     </a>",
"    </li>",
"    <li>",
"     Buie, DH, Malltsberger, JT. The psychological vulnerability to suicide. In: Suicide: Understanding and Responding, Jacobs, D, Brown, NH (Eds), International Universities Press, Madison 1989. p.59.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/58\">",
"      Conner KR, Cox C, Duberstein PR, et al. Violence, alcohol, and completed suicide: a case-control study. Am J Psychiatry 2001; 158:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/59\">",
"      Blumenthal SJ, Kupfer DJ. Generalizable treatment strategies for suicidal behavior. Ann N Y Acad Sci 1986; 487:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/60\">",
"      Ajdacic-Gross V, Ring M, Gadola E, et al. Suicide after bereavement: an overlooked problem. Psychol Med 2008; 38:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/61\">",
"      V&auml;rnik A, K&otilde;lves K, Wasserman D. Suicide among Russians in Estonia: database study before and after independence. BMJ 2005; 330:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/62\">",
"      Silenzio VM, Pena JB, Duberstein PR, et al. Sexual orientation and risk factors for suicidal ideation and suicide attempts among adolescents and young adults. Am J Public Health 2007; 97:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/63\">",
"      Gunnell D, Magnusson PK, Rasmussen F. Low intelligence test scores in 18 year old men and risk of suicide: cohort study. BMJ 2005; 330:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/64\">",
"      Qin P, Mortensen PB. The impact of parental status on the risk of completed suicide. Arch Gen Psychiatry 2003; 60:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/65\">",
"      Stack S, Lester D. The effect of religion on suicide ideation. Soc Psychiatry Psychiatr Epidemiol 1991; 26:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/66\">",
"      Isomets&auml; ET, Aro HM, Henriksson MM, et al. Suicide in major depression in different treatment settings. J Clin Psychiatry 1994; 55:523.",
"     </a>",
"    </li>",
"    <li>",
"     Michel, K. Suicide prevention and primary care. In: The International Handbook of Suicide and Attempted Suicide, Hawton, K, Heeringen, KV (Eds), Wiley, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/68\">",
"      Pirkis J, Burgess P, Jolley D. Suicide among psychiatric patients: a case-control study. Aust N Z J Psychiatry 2002; 36:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/69\">",
"      Kapur N, Cooper J, Rodway C, et al. Predicting the risk of repetition after self harm: cohort study. BMJ 2005; 330:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/70\">",
"      McMillan D, Gilbody S, Beresford E, Neilly L. Can we predict suicide and non-fatal self-harm with the Beck Hopelessness Scale? A meta-analysis. Psychol Med 2007; 37:769.",
"     </a>",
"    </li>",
"    <li>",
"     Draft guidelines for the identification and assessment of suicidality. Forum. Risk Management Foundation of the Harvard Medical Institutions, Ryan, EM (Eds) 1993. p.14.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/72\">",
"      Kragh-S&oslash;rensen P. Pharmacotherapy of the suicidal patient. Acta Psychiatr Scand Suppl 1993; 371:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/73\">",
"      Molcho A, Stanley M. Antidepressants and suicide risk: issues of chemical and behavioral toxicity. J Clin Psychopharmacol 1992; 12:13S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/74\">",
"      Prudic J, Sackeim HA. Electroconvulsive therapy and suicide risk. J Clin Psychiatry 1999; 60 Suppl 2:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/75\">",
"      Stanford EJ, Goetz RR, Bloom JD. The No Harm Contract in the emergency assessment of suicidal risk. J Clin Psychiatry 1994; 55:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/76\">",
"      Miller MC, Jacobs DG, Gutheil TG. Talisman or taboo: the controversy of the suicide-prevention contract. Harv Rev Psychiatry 1998; 6:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/77\">",
"      Brown GK, Ten Have T, Henriques GR, et al. Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA 2005; 294:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/78\">",
"      Isacsson G. Suicide prevention--a medical breakthrough? Acta Psychiatr Scand 2000; 102:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/79\">",
"      Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/80\">",
"      Isacsson G, Bo&euml;thius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand 1992; 85:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/81\">",
"      Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/82\">",
"      King EA, Baldwin DS, Sinclair JM, et al. The Wessex Recent In-Patient Suicide Study, 1. Case-control study of 234 recently discharged psychiatric patient suicides. Br J Psychiatry 2001; 178:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/83\">",
"      Rose S, Bisson J, Churchill R, Wessely S. Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2002; :CD000560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/84\">",
"      van Emmerik AA, Kamphuis JH, Hulsbosch AM, Emmelkamp PM. Single session debriefing after psychological trauma: a meta-analysis. Lancet 2002; 360:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/85\">",
"      Gist R, Devilly GJ. Post-trauma debriefing: the road too frequently travelled. Lancet 2002; 360:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/86\">",
"      Rose S, Bisson J, Wessely S. A systematic review of single-session psychological interventions ('debriefing') following trauma. Psychother Psychosom 2003; 72:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10377/abstract/87\">",
"      U.S. Preventive Services Task Force. Screening for suicide risk: recommendation and rationale. Ann Intern Med 2004; 140:820.",
"     </a>",
"    </li>",
"    <li>",
"     Canadian Task Force on Preventive Health Care. www.ctfphc.org (Accessed 3/7/05).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1708 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10377=[""].join("\n");
var outline_f10_8_10377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hopelessness and impulsivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History of previous suicide attempts or threats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Age, sex, and race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Marital status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Occupation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adverse childhood experiences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Family history and genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROTECTIVE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Suicidal ideation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reducing immediate risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Contracting for safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Managing underlying factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Monitoring and follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      POST SUICIDE INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=related_link\">",
"      Effect of antidepressants on suicide risk in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_8_10378="Shoulder dislocation and reduction";
var content_f10_8_10378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Shoulder dislocation and reduction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10378/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10378/contributors\">",
"     Scott C Sherman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10378/contributors\">",
"     Jeffrey Schaider, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10378/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10378/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/8/10378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/8/10378/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/8/10378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder dislocations account for 50 percent of all major joint dislocations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Anterior dislocation is most common, accounting for 95 to 97 percent of cases. Posterior dislocation accounts for 2 to 4 percent, and inferior dislocation (ie, luxatio erecta, which means \"to place upward\") accounts for 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the mechanism of injury, evaluation, and reduction of shoulder dislocations. Evaluation of the patient with shoulder pain and other shoulder injuries are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10663?source=see_link\">",
"     \"Acromioclavicular joint injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33912?source=see_link\">",
"     \"Frozen shoulder (adhesive capsulitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=see_link\">",
"     \"Glenohumeral osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41592?source=see_link\">",
"     \"Multidirectional instability of the shoulder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=see_link\">",
"     \"Shoulder impingement syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The shoulder is an inherently unstable joint (",
"    <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"UTD.htm?35/8/35978\">",
"     figure 1A-C",
"    </a>",
"    ). The glenoid is shallow, allowing for a wide range of motion, with only a small portion of the humeral head articulating with the glenoid in any position. The glenoid labrum is a fibrocartilaginous structure that surrounds the glenoid and inserts into the edge of the joint capsule. The distal portion of the joint capsule attaches to the humeral neck. The inferior glenohumeral ligament represents the anterior-inferior portion of the capsule. This ligament is thicker than the rest of the joint capsule and provides the strongest impediment to anterior dislocation.",
"   </p>",
"   <p>",
"    The rotator cuff muscles provide additional support of the glenohumeral joint. The subscapularis muscle lies anterior to the joint capsule and acts as a secondary support resisting dislocation. Posteriorly the supraspinatus, infraspinatus, and teres minor pull the humeral head into the glenoid and help to prevent it from anterior subluxation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The axillary nerve, the nerve most often injured with shoulder dislocations, runs inferiorly to the humeral head and wraps around the surgical neck of the humerus. It innervates the deltoid and teres minor muscles and the skin overlying the lateral shoulder (\"shoulder badge\" distribution). Shoulder anatomy is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the patient with shoulder complaints\", section on 'Anatomy and biomechanics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of a shoulder dislocation need a thorough examination and frequently radiographic imaging to diagnose dislocation and associated injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anterior shoulder dislocation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mechanism of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anterior shoulder dislocation is usually caused by a blow to the abducted, externally rotated, and extended arm (eg, blocking a basketball shot). Less commonly, a blow to the posterior humerus or a fall on an outstretched arm may cause an anterior dislocation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anteriorly dislocated shoulder causes the arm to be slightly abducted and externally rotated. The patient resists all movement. The acromion appears prominent in thin individuals and there is loss of the normal rounded appearance of the shoulder (",
"    <a class=\"graphic graphic_picture graphicRef60699 \" href=\"UTD.htm?0/17/273\">",
"     picture 1",
"    </a>",
"    ). Clinicians perform a neurovascular examination paying particular attention to distal pulses and the function of the axillary nerve, which is most commonly injured in anterior shoulder dislocations. Axillary nerve dysfunction manifests as loss of sensation in a \"shoulder badge\" distribution, although this finding is not reliably present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Deltoid muscle weakness may also be present, but is impractical to assess during the acute injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/10\">",
"     10",
"    </a>",
"    ]. Some degree of axillary nerve dysfunction is present in 42 percent of patients with an anterior dislocation, but most patients recover completely without intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. In many cases, dysfunction resolves with reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Radiographic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians obtain radiographs before and after reduction of an anterior shoulder dislocation. Initial x-rays confirm the diagnosis and exclude fractures; postreduction x-rays confirm successful reduction and exclude any fracture caused by the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/13\">",
"     13",
"    </a>",
"    ]. In some cases there is no need for prereduction x-rays.",
"   </p>",
"   <p>",
"    Clinically important fractures occur with approximately 25 percent of shoulder dislocations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. According to a retrospective case-control study, factors associated with fracture include age over 40, first-time dislocation, and traumatic mechanism (eg, fight or fall) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/14\">",
"     14",
"    </a>",
"    ]. When all three factors are absent, the negative predictive value for the presence of a fracture is 96.6 percent (95% CI 88.3-99.6). Based on this study and other observational data, we feel prereduction radiographs are unnecessary if none of the listed criteria are met and the clinician feels certain of the diagnosis of an anterior shoulder dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine films include an anteroposterior (AP), a scapular \"Y\" view, and an axillary view. The diagnosis of an anterior shoulder dislocation may be straightforward and is often easily visualized on the AP view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81951 \" href=\"UTD.htm?30/13/30943\">",
"     image 1",
"    </a>",
"    ). The dislocated humeral head usually lies in a subcoracoid position (",
"    <a class=\"graphic graphic_figure graphicRef64651 \" href=\"UTD.htm?21/21/21843\">",
"     figure 2",
"    </a>",
"    ). If the humeral head is subclavicular or subglenoid, there has been a greater degree of displacement and a concomitant greater tuberosity fracture or rotator cuff tear is usually present (",
"    <a class=\"graphic graphic_figure graphicRef64651 \" href=\"UTD.htm?21/21/21843\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The scapular \"Y\" view is taken with the beam directed parallel to the scapular body. The \"Y\" is formed by the body, spine, and coracoid process. The glenoid falls in the center of the \"Y\" and is normally obscured by the humeral head. When an anterior dislocation is present, the humeral head appears medial to the \"Y\" (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72538 \" href=\"UTD.htm?31/13/31967\">",
"     image 2",
"    </a>",
"    ). There may be false negatives with the scapular view, so an axillary view should also be obtained.",
"   </p>",
"   <p>",
"    The axillary view is taken with the patient's arm abducted. The radiograph plate is placed on the patients shoulder and the x-ray beam projects through the axilla to the plate (",
"    <a class=\"graphic graphic_picture graphicRef81658 \" href=\"UTD.htm?25/30/26080\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61746 \" href=\"UTD.htm?33/39/34431\">",
"     image 3",
"    </a>",
"    ). The patient's arm need not be abducted 90 degrees, as this position causes pain. About 10 to 15 degrees of abduction, or just enough to get the x-ray tube between the patient's arm and hip, is usually sufficient to obtain the appropriate view. Alternatively, a Velpeau axillary view can be obtained in which the patient leans back 15 degrees over the edge of a table and the beam is directed from above the shoulder to the plate placed on the edge of the table.",
"   </p>",
"   <p>",
"    Another view that may be helpful in determining the presence of a dislocation is the true AP (Grashey) view in which the beam is directed at a 45 degree angle in a medial to lateral direction with the x-ray plate just posterior and parallel to the scapular body. This view helps clinicians assess for subtle joint incongruities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Associated injuries (Hill-Sachs and Bankart)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associated fractures identified on plain radiographs include Hill-Sachs deformities, Bankart lesions, and greater tuberosity fractures. A Hill-Sachs deformity is a cortical depression in the humeral head created by the glenoid rim during dislocation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57243 \" href=\"UTD.htm?41/9/42142\">",
"     image 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/18\">",
"     18",
"    </a>",
"    ]. They occur in 35 to 40 percent of anterior dislocations and are seen on the AP radiograph with the arm in internal rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/7\">",
"     7",
"    </a>",
"    ]. Bankart lesions occur when the glenoid labrum is disrupted during dislocation and a bone fragment is avulsed (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54398 \" href=\"UTD.htm?8/44/8911\">",
"     image 5",
"    </a>",
"    ). Bony Bankart lesions are present in 5 percent of patients, while soft tissue Bankart lesions (no bone is avulsed) occur in approximately 90 percent of patients less than 30 years old with an anterior shoulder dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/11,19\">",
"     11,19",
"    </a>",
"    ]. Greater tuberosity fractures are present in 10 percent of patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59097 \" href=\"UTD.htm?9/56/10113\">",
"     image 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/20\">",
"     20",
"    </a>",
"    ]. Indications for orthopedic referral, including selected Bankart and Hill-Sachs lesions, are discussed separately. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Operative treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Posterior shoulder dislocation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanism of injury &ndash; A blow to the anterior portion of the shoulder, axial loading of an adducted and internally rotated arm, or violent muscle contractions following a seizure or electrocution represent the most common causes of posterior shoulder dislocation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/21-23\">",
"       21-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Examination &ndash; Examination reveals prominence of the posterior shoulder with flattening anteriorly. The coracoid process appears prominent. The patient holds the arm in adduction and internal rotation and is unable to externally rotate (",
"      <a class=\"graphic graphic_picture graphicRef73358 \" href=\"UTD.htm?43/9/44178\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef54900 \" href=\"UTD.htm?13/20/13632\">",
"       movie 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiographic evaluation &ndash; Radiographic evidence of a posterior shoulder dislocation on a standard anteroposterior (AP) view is subtle and may go undetected in up to 50 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/25\">",
"       25",
"      </a>",
"      ]. Clues to the diagnosis include the \"light bulb\" sign, rim sign, and trough line sign (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61746 \" href=\"UTD.htm?33/39/34431\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54093 \" href=\"UTD.htm?16/38/16994\">",
"       image 7",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The light bulb sign manifests because the humeral head is internally rotated and the tuberosities no longer project laterally, resulting in a circular appearance of the humeral head (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54093 \" href=\"UTD.htm?16/38/16994\">",
"       image 7",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/26\">",
"       26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The rim sign refers to the distance from the medial aspect of the humeral head to the anterior glenoid rim. Although this distance may be normal with a posterior dislocation, if there is superimposition of these two structures or conversely a widened joint space (&gt;6 mm), posterior dislocation should be suspected (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61746 \" href=\"UTD.htm?33/39/34431\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54093 \" href=\"UTD.htm?16/38/16994\">",
"       image 7",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The trough line sign is present when two parallel lines of cortical bone are seen on the medial cortex of the humeral head. One line represents the medial cortex of the humeral head, while the other line represents the \"trough\" of an impaction fracture (referred to as the \"reverse Hill-Sachs lesion\") on the anterior articular surface of the humeral head [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Posterior shoulder dislocations are commonly associated with tuberosity and surgical neck fractures of the humerus, reverse Hill-Sachs lesions, and injuries to the labrum and rotator cuff [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. In cases where plain radiographs are indeterminate for dislocation, computed tomography is diagnostic and reveals the size of the articular surface impaction fracture, enabling the orthopedic surgeon to determine the most appropriate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inferior shoulder dislocation (luxatio erecta)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanism of injury &ndash; Inferior dislocations are most commonly caused by axial loading with the arm fully abducted or forceful hyperabduction of the arm [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/30\">",
"       30",
"      </a>",
"      ]. This dislocation frequently occurs when patients fall and suddenly grasp on to an object above their head resulting in hyperabduction.",
"     </li>",
"     <li>",
"      Examination &ndash; Patients with this injury hold the involved arm above their head and are unable to adduct the arm [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/31\">",
"       31",
"      </a>",
"      ]. The forearm is pronated and in most cases rests on the top of the head. Approximately 60 percent of patients will have some degree of neurologic dysfunction, with the axillary nerve most commonly involved [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/32\">",
"       32",
"      </a>",
"      ]. In most cases, neurologic dysfunction resolves spontaneously following reduction. Rotator cuff tears or greater tuberosity fractures are present in 80 percent of cases. Arterial injury occurs in approximately 3 percent of patients, and can manifest as an absent or discrepant pulse [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiographic evaluation &ndash; Radiographs reveal the humeral head beneath the coracoid or the glenoid (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70882 \" href=\"UTD.htm?39/17/40223\">",
"       image 8",
"      </a>",
"      ). Associated fractures include the greater tuberosity (most common), acromion, scapula, humeral head, coracoid, and glenoid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     REDUCTION PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inform the patient of the risks specific to the agents to be used, if procedural sedation is planned. The risks of the procedure itself are minimal and include the rare incidence of fractures of the humerus, glenoid, or coracoid process. Rotator cuff injuries may also occur, but are usually present prior to reduction. Axillary artery or nerve injury may occur during reduction, especially with techniques that require a significant amount of traction, but such complications are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the reduction technique, no materials may be required. Approximately 10 to 15 pounds of weights are needed for the Stimson technique; bed sheets are used with the traction-countertraction technique. An assistant is required for many of the reduction techniques. If procedural sedation is deemed necessary, a nurse is required to prepare medications, administer oxygen, place the patient on appropriate monitors, and place an IV. Airway management equipment is moved to the bedside if procedural sedation is to be provided. One percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , a 20 mL syringe, and a 20 gauge needle are needed when intraarticular lidocaine injection is given for analgesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delays in reducing dislocated shoulders may be necessary due to the need to treat life or limb-threatening conditions. Obtain orthopedic surgery consultation for elderly patients with dislocations that present subacutely (after 7 to 10 days) because of the relatively high incidence of vascular injury and fractures that occur with reduction attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consultation with an orthopedic surgeon should also be obtained when a surgical neck fracture is identified concomitantly with an anterior shoulder dislocation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83568 \" href=\"UTD.htm?18/6/18531\">",
"     image 9",
"    </a>",
"    ). An attempt at closed reduction in such cases is likely to displace the fracture or worsen existing displacement, and may increase the likelihood of avascular necrosis of the humeral head.",
"   </p>",
"   <p>",
"    Reduction can frequently be obtained without analgesia in patients with anterior dislocations that are recent (ie, less than 24 hours), recurrent, or relatively atraumatic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/10\">",
"     10",
"    </a>",
"    ]. This approach is attractive because it is rapid, avoids complications from medications, and requires fewer personnel. Reduction without analgesia works best with techniques that do not require significant traction (ie, external rotation, scapular manipulation, or Milch technique) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Procedural sedation and analgesia (PSA) is administered to relieve pain and to reduce spasm in the muscles of the rotator cuff. Common medications include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Propofol and etomidate are particularly useful because of their rapid onset, short duration of action, and infrequent side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If PSA is used, continuous monitoring with capnography and pulse oximetry is required, as well as frequent blood pressure measurements. Monitoring begins before any medications are given and continues until the patient is fully awake and able to protect their airway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraarticular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is inexpensive, provides pain relief, avoids potential complications from intravenous sedatives, and results in a rapid recovery time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. We suggest it be used in patients with comorbidities that put them at risk of complications from procedural sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/41\">",
"     41",
"    </a>",
"    ]. Injection is not made through skin or soft tissue that shows signs of infection. Coagulation disorders are a relative contraindication. Intraarticular injection fails more often in patients presenting more than six hours after injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lateral injection approach is best when the humoral head is dislocated anteriorly. To perform the injection, identify the acromion process over the lateral aspect of the shoulder. The injection is made laterally, approximately 1 cm inferior to the acromion process. After cleaning the skin and providing local skin anesthesia, inject 20 mL of 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    using an 18 or 20 gauge needle into the glenohumeral joint. Direct the needle medially and inferiorly, and advance to a depth of 2.5 to 3.0 cm. Use of ultrasound guidance helps to ensure injection in the proper location [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of five randomized trials (211 patients) comparing intraarticular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    and PSA reported no significant difference in the rate of successful shoulder reduction but found more adverse effects (RR 0.16; 95% CI 0.06-0.43) and a longer mean time spent in the emergency department among patients given PSA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the rate of adverse effects from PSA differs substantially according to the medications used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anterior shoulder dislocation reduction",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clear evidence exists supporting the superiority of any one of the many methods used to reduce anterior shoulder dislocations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/46\">",
"     46",
"    </a>",
"    ]. The method employed depends on clinician preference and the patient's condition. Generally, a technique that is quick, simple, and requires neither significant force nor intravenous medication is ideal. We suggest starting with scapular manipulation, and if unsuccessful, next attempting the external rotation technique (with or without the Milch technique). If reduction is not accomplished using these approaches, then traction-countertraction or the Stimson technique can be used. The techniques are described below.",
"   </p>",
"   <p>",
"    Successful reduction is heralded by a \"clunk\" as the humeral head relocates and the return of the normal contour of the shoulder. With more gradual techniques (eg, external rotation), reduction may be more subtle with no appreciable \"clunk\". The ability of the patient to place the hand of the affected extremity on the opposite shoulder further confirms reduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pediatric considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic glenohumeral dislocation in children less than 10 years is rare, accounting for less than two percent of all cases. Closed reduction is usually possible using the same techniques as adults. Nevertheless, because of the possibility of concomitant physeal (ie, growth plate) fractures, we recommend orthopedic consultation prior to any attempt at reduction, unless vascular compromise necessitates immediate treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Reduction techniques",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Scapular manipulation",
"      </strong>",
"      &ndash; Scapular manipulation is quick, easy, and well tolerated by the patient and therefore is a good first maneuver. The method employs rotation of the scapula to disengage the humeral head from the glenoid and allow it to reduce into the glenoid. Success rates range from 80 to 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/48-51\">",
"       48-51",
"      </a>",
"      ]. The procedure takes one to five minutes and premedication is generally unnecessary. It is easiest to perform with the patient upright, but can also be performed with the patient prone if necessary.",
"     </li>",
"     <li>",
"      <strong>",
"       Upright technique (preferred)",
"      </strong>",
"      &ndash; Place the head of the bed at 90 degrees. Have the patient dangle their legs over the side of the gurney and rest their unaffected shoulder against the upright portion of the bed. Encourage the patient to relax their shoulder muscles. Stand behind the patient and locate the scapula. Then simultaneously push the tip medially and the acromion inferiorly using the thumbs, thereby rotating the scapula. At the same time, an assistant provides",
"      <strong>",
"       gentle",
"      </strong>",
"      forward or downward traction on the arm [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. Downward traction avoids movement of the patient's arm and may be advantageous. To exert downward traction, the assistant grabs the patient's wrist with one hand and the already flexed elbow with the other hand and pushes down on the elbow while holding the wrist in place (",
"      <a class=\"graphic graphic_picture graphicRef57540 \" href=\"UTD.htm?6/0/6147\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef68113 \" href=\"UTD.htm?23/45/24272\">",
"       movie 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Prone technique",
"      </strong>",
"      &ndash; The arm hangs off the side of the stretcher and is allowed to drop towards the ground. About 10 to 15 pounds of weight are hung from a prefabricated wrist splint as an alternative to an assistant providing traction [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/51\">",
"       51",
"      </a>",
"      ]. The scapula is manipulated in similar fashion to the upright approach.",
"     </li>",
"     <li>",
"      <strong>",
"       External rotation technique",
"      </strong>",
"      &ndash; The external rotation technique reduces anterior glenohumeral dislocation by overcoming spasm of the internal rotators of the humerus, unwinding the joint capsule, and enabling the external rotators of the rotator cuff to pull the humerus posteriorly [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. This method is safe, easy to understand and teach, has no reported complications, and requires only one clinician [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. It is successful in 80 to 90 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/56,58\">",
"       56,58",
"      </a>",
"      ]. In one small case series, 81 percent of patients who were successfully treated required no sedation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/56\">",
"       56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      To perform the technique, the patient lies supine and the elbow is flexed to 90 degrees to relax the long head of the biceps and allow movement of the humeral head [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/20\">",
"       20",
"      </a>",
"      ]. Grasp the elbow with one hand to maintain the adducted position of the arm and with the other hand hold the patient's wrist. SLOWLY, the patient is asked to let their arm fall to the side (externally rotate) as the clinician guides the hand (",
"      <a class=\"graphic graphic_picture graphicRef75869 \" href=\"UTD.htm?36/42/37537\">",
"       picture 5",
"      </a>",
"      ). Whenever pain or spasm is felt, the movement is stopped and the muscles are allowed to relax. Gradually, over the course of 5 to 10 minutes, the arm externally rotates sufficiently that reduction can occur. Reduction generally happens with the arm externally rotated between 70 to 110 degrees [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/59\">",
"       59",
"      </a>",
"      ]. Often the reduction is subtle and the \"clunk\" of the humerus rearticulating with the glenoid, typical of more forceful reduction techniques, is not appreciable. A video of the technique is provided (",
"      <a class=\"graphic graphic_movie graphicRef81132 \" href=\"UTD.htm?24/22/24928\">",
"       movie 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Milch technique",
"      </strong>",
"      &ndash; If reduction is not achieved with the external rotation approach, even after the arm is fully externally rotated, the Milch technique can be added. To perform this technique, abduct the now fully externally rotated arm into an overhead position, maintaining external rotation throughout the abduction. Reduction is achieved by applying gentle traction in line with the humerus and direct pressure over the humeral head with the clinician's thumb in the axilla (",
"      <a class=\"graphic graphic_picture graphicRef62609 \" href=\"UTD.htm?6/55/7026\">",
"       picture 6",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Milch surmised that in the overhead position the muscles about the shoulder were in alignment with one another, and with cross-stresses thereby eliminated, nothing would prevent reduction of the humeral head [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. Success rates of this technique range from 86 to 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/34,62-64\">",
"       34,62-64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Stimson technique",
"      </strong>",
"      &ndash; If the above techniques are unsuccessful, one alternative method is Stimson's technique, which involves placing the patient prone and hanging the affected extremity off the edge of the bed with 10 to 15 pounds of weight (",
"      <a class=\"graphic graphic_picture graphicRef76757 \" href=\"UTD.htm?43/25/44434\">",
"       picture 7",
"      </a>",
"      ). Reduction is usually achieved within 30 minutes.",
"     </li>",
"     <li>",
"      <strong>",
"       Traction countertraction",
"      </strong>",
"      &ndash; Traction-countertraction employs a sheet wrapped under the axilla. While one assistant provides gentle continuous traction at the wrist or elbow, the other provides countertraction with the sheet from the opposite side of the patient (",
"      <a class=\"graphic graphic_picture graphicRef55723 \" href=\"UTD.htm?27/50/28451\">",
"       picture 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef60981 \" href=\"UTD.htm?0/33/530\">",
"       movie 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Spaso technique",
"      </strong>",
"      &ndash; The Spaso technique employs gentle vertical traction and external rotation in the supine patient to reduce the dislocation, usually within one to two minutes (",
"      <a class=\"graphic graphic_picture graphicRef69081 \" href=\"UTD.htm?28/47/29427\">",
"       picture 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/65,66\">",
"       65,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Fares technique",
"      </strong>",
"      &ndash; In this technique, the patient lies supine on a stretcher with the affected upper extremity at their side. The clinician grasps the patient&rsquo;s wrist and gently pulls the arm to provide traction. No counter-traction is used. The arm is gradually abducted while the clinician continuously moves the arm up and down in an arc of approximately 10 cm. The up and down motion helps relax the shoulder musculature. If the shoulder has not reduced by 90 degrees of abduction, external rotation is added. A video of the technique is provided (",
"      <a class=\"graphic graphic_movie graphicRef83572 \" href=\"UTD.htm?0/12/196\">",
"       movie 5",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In a randomized trial, the Fares technique performed comparably to the external rotation technique (76 of 80 [95 percent] shoulders reduced versus 73 of 80 [91 percent] shoulders reduced respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Cunningham technique",
"      </strong>",
"      &ndash; To perform this technique, the clinician sits in front of the patient, who assumes a comfortable sitting position [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/68\">",
"       68",
"      </a>",
"      ]. The patient places the hand on the affected side atop the clinician&rsquo;s shoulder. The clinician rests one arm gently in the patient&rsquo;s elbow crease while the other hand gently massages the patient&rsquo;s biceps, deltoid, and trapezius muscles to help them relax. While encouraging the patient to relax, the clinician instructs the patient to pull their shoulder blades together and straighten their back. This maneuver moves the scapula medially and removes the major obstacle preventing reduction of the humeral head.",
"     </li>",
"     <li>",
"      <strong>",
"       Other approaches",
"      </strong>",
"      &ndash; Other methods include, the wrestling technique [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/69\">",
"       69",
"      </a>",
"      ], chair technique [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/70\">",
"       70",
"      </a>",
"      ], Eskimo technique [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/71\">",
"       71",
"      </a>",
"      ], Hippocratic technique [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/72\">",
"       72",
"      </a>",
"      ], and Kocher's method [",
"      <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/73\">",
"       73",
"      </a>",
"      ]. These techniques are either more complex or associated with undesirable complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Hippocratic technique involves traction-countertraction with the clinician's foot placed in the patient's axilla. Kocher's method uses in-line traction of the patient's arm while it is abducted 45 degrees. While traction is maintained, the arm is externally rotated and the elbow is brought across the chest to the midline. Next, the arm is internally rotated until the patient's hand touches their shoulder. Both the Hippocratic and Kocher techniques are associated with a high rate of fractures, brachial plexus injury, and vascular injury compared with other techniques and should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Posterior shoulder dislocation reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest obtaining consultation with an orthopedic surgeon for all cases of posterior shoulder dislocation. Closed reduction is only attempted if the anterior articular surface defect (\"reverse Hill-Sachs deformity\") is less than 20 percent of the entire articular surface and the duration of dislocation is less than three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. Closed reduction is frequently performed in the operating room under general anesthesia, but may be accomplished in the emergency department with procedural sedation.",
"   </p>",
"   <p>",
"    Reduction involves axial traction on the adducted arm with the elbow flexed. Sheets are used in a similar manner to the traction-countertraction method to reduce an anterior dislocation (",
"    <a class=\"graphic graphic_picture graphicRef78488 \" href=\"UTD.htm?34/30/35298\">",
"     picture 10",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/3\">",
"     3",
"    </a>",
"    ]. While traction is applied, the arm is externally rotated. Direct pressure directed anteriorly on the displaced humeral head or gentle lateral traction using a sheet looped under the axilla to unlock the glenoid rim may assist reduction. If successful, the arm is immobilized in a neutral position [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Inferior shoulder dislocation reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction of luxatio erecta (inferior shoulder dislocation) is achieved by traction-countertraction in line with the abducted humerus. Gentle, gradual adduction of the arm reduces the dislocation (",
"    <a class=\"graphic graphic_picture graphicRef50866 \" href=\"UTD.htm?20/34/21028\">",
"     picture 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/6,74,75\">",
"     6,74,75",
"    </a>",
"    ]. Closed reduction is successful in most cases, unless a \"buttonhole\" deformity (humeral head is trapped in a tear of the inferior capsule) exists, in which case open surgical reduction is required [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction of an anterior shoulder dislocation in the emergency department is unsuccessful in 5 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/7\">",
"     7",
"    </a>",
"    ]. Interposition of the biceps tendon, joint capsule, or fracture fragments within the joint is the most common cause [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/7,76\">",
"     7,76",
"    </a>",
"    ]. Postreduction radiographs are necessary only if the clinician is uncertain whether the reduction has been successful. Postreduction radiographs are unlikely to identify a clinically significant fracture if none was identified on prereduction x-rays [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/16,17,77-79\">",
"     16,17,77-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nerve and vascular injuries are rare complications of shoulder dislocation reduction. Nerve injury, most often of the axillary nerve, occurs more often in the elderly and possibly when methods that employ traction on the abducted arm are used [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/9\">",
"     9",
"    </a>",
"    ]. Axillary nerve injury is managed conservatively. After four weeks, an EMG and nerve conduction study is performed. If surgery is necessary, it is best performed within three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/80\">",
"     80",
"    </a>",
"    ]. Other less common nerve injuries include damage to the brachial plexus, radial, ulnar, and musculocutaneous nerves. Shoulder dislocation accounts for 7 percent of brachial plexus injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/81\">",
"     81",
"    </a>",
"    ]. Treatment is conservative (ie, physical therapy) and recovery generally occurs within three to four months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Axillary artery injury from attempts at shoulder reduction is rare, but more common in older patients with chronic dislocations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/8\">",
"     8",
"    </a>",
"    ]. Approximately 200 cases of axillary artery injury due to anterior shoulder dislocation have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/83\">",
"     83",
"    </a>",
"    ]. Approximately 90 percent of these injuries occur in patients over the age of 50 due to joint capsule adhesions and atherosclerosis with loss of vessel elasticity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/84\">",
"     84",
"    </a>",
"    ]. If arterial injury is suspected based on increasing upper extremity pain, a diminished pulse, or a large hematoma, emergent reduction followed by axillary angiography is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Venous injury rarely occurs, but usually presents as pain and swelling in the extremity from venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rotator cuff tears after anterior shoulder dislocations are uncommon in younger patients, but occur in over half of patients over the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/8\">",
"     8",
"    </a>",
"    ]. A complete rotator cuff tendon tear exists in 14 percent of patients with shoulder dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/86\">",
"     86",
"    </a>",
"    ]. Diagnosing a rotator cuff tear is difficult immediately after an injury, but is often noted during follow-up by difficulty or pain when the patient abducts the arm. Such tears may be difficult to distinguish from axillary nerve injuries, which also present with abduction difficulty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glenoid bone loss is a potential long-term complication of shoulder dislocation, not of reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After successful reduction of an anterior shoulder dislocation, the shoulder is immobilized and the patient is referred to an orthopedic surgeon within one week. The most common complication of shoulder dislocation is recurrent dislocation, which occurs in 50 to 90 percent of patients under the age of 20 and in approximately 5 to 10 percent of patients over age 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/7,8,88-90\">",
"     7,8,88-90",
"    </a>",
"    ]. Efforts to prevent redislocation include altering the position of immobilization, increasing the duration of immobilization, physical therapy, and operative repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best position in which to immobilize the shoulder after reduction remains controversial. We suggest immobilizing the shoulder in the traditional position of adduction and internal rotation. A collar and cuff, sling and swathe, or a commercially available shoulder immobilizer are equally effective.",
"   </p>",
"   <p>",
"    In patients under 30 years old, the shoulder is immobilized for three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/88,91-93\">",
"     88,91-93",
"    </a>",
"    ]. In patients over 30 years old, the rate of redislocation is lower and early mobilization (after one week) is needed to limit joint stiffness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/10,11,88,93\">",
"     10,11,88,93",
"    </a>",
"    ]. Gentle pendular motion exercises should be performed during the immobilization period to reduce the risk of frozen shoulder.",
"   </p>",
"   <p>",
"    Cadaveric studies, small observational and randomized trials, and a systematic review had suggested that recurrent dislocation might be less likely if the shoulder were immobilized in 10 degrees of external rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/91,94-96\">",
"     91,94-96",
"    </a>",
"    ]. This approach was based on the commonly held belief that detachment of the glenoid labrum (ie, Bankart lesion) is the major reason for high redislocation rates among younger patients. If the shoulder were immobilized in external rotation, the damaged and intact parts of the glenoid labrum would lie closer to one another and be more likely to heal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/94,97-99\">",
"     94,97-99",
"    </a>",
"    ]. While this theory makes intuitive sense, subsequent randomized trials have failed to demonstrate lower redislocation rates among patients who were immobilized in external rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Operative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early indications for surgery include irreducible dislocations, displaced greater tuberosity fractures, and Bankart fractures that create glenohumeral instability [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/11\">",
"     11",
"    </a>",
"    ]. A Bankart fracture involving a bone fragment greater than 20 percent of the area of the inferior glenoid is generally considered &ldquo;critical&rdquo; and requires urgent orthopedic referral [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. If the clinician has any doubt about the size or area of involvement of a Bankart lesion, it is best to obtain orthopedic referral. Bankart and Hill-Sachs lesions are described above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Associated injuries (Hill-Sachs and Bankart)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Arthroscopic repair of a soft tissue Bankart lesion is sometimes recommended in young (less than 30), first time dislocators that engage in highly demanding physical activities because surgery reduces the high rate of subsequent redislocation in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/10,19,104-108\">",
"     10,19,104-108",
"    </a>",
"    ]. Generally, repair is performed within 10 days. Late surgical indications include recurrent instability or activity limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Orthopedic referral should be obtained for significant Hill-Sachs lesions. Injuries may be managed non-operatively if the bony defect is small (&lt;20 percent of the articular surface of the humeral head) and the glenohumeral joint remains stable during desired activities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intensive rehabilitation program may reduce the rate of redislocation, but this is not universally true [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/105,110,111\">",
"     105,110,111",
"    </a>",
"    ]. During the initial period of immobilization (usually three weeks), the patient wears the immobilizer at all times unless bathing, mobilizing the elbow and wrist, or performing Codman's exercises (gentle shoulder range of motion exercises with the arm suspended). Abduction and external rotation must be avoided because these motions stress the anterior capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In subsequent weeks, active-assisted range of motion exercises and then isometric strengthening exercises for the muscles of internal rotation and adduction are added to the program. Generally, by week 12, limited return to sporting activities is permitted, followed by full return to sporting activities as tolerated by week 16 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/88,104,106\">",
"     88,104,106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can be taught to reduce their own shoulder dislocation by clasping their hands together around the flexed ipsilateral knee from a seated position. The patient then leans back slowly and extends the hip, pausing whenever the pain is too much, until reduction occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/8/10378/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder (ie, glenohumeral) dislocations account for 50 percent of all major joint dislocations. Anterior dislocations comprise the large majority of these. Shoulder anatomy and mechanisms of dislocation are discussed above. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior dislocation &ndash; An anteriorly dislocated shoulder causes the arm to be slightly abducted and externally rotated. The patient resists all movement and the acromion appears prominent (",
"      <a class=\"graphic graphic_picture graphicRef60699 \" href=\"UTD.htm?0/17/273\">",
"       picture 1",
"      </a>",
"      ). Proper evaluation includes a neurovascular examination, with particular attention to distal pulses and the function of the axillary nerve, which is most commonly injured. X-rays routinely obtained include the anteroposterior (AP), the scapular \"Y\" view, and the axillary view (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81951 \" href=\"UTD.htm?30/13/30943\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72538 \" href=\"UTD.htm?31/13/31967\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anterior shoulder dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinically important fractures occur with approximately 25 percent of anterior shoulder dislocations. Factors associated with fracture include age over 40, first-time dislocation, and traumatic mechanism (eg, fight or fall). When all three factors are absent, the negative predictive value for the presence of a fracture is generally extremely high. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anterior shoulder dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduction technique &ndash; No clear evidence exists supporting the superiority of any one of the many methods used to reduce anterior shoulder dislocations. Techniques that are quick, simple, and require neither significant force nor intravenous medication are ideal. We therefore suggest starting with scapular manipulation, and if unsuccessful next attempting the external rotation technique (with or without the Milch technique). If reduction is not accomplished using these approaches, then traction-countertraction can be used. Each technique is described in the text, along with appropriate analgesia and monitoring, and potential complications. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Reduction procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immobilization &ndash; We suggest that following reduction of an anterior shoulder dislocation the patient's injured arm be immobilized in a position of adduction and internal rotation. A collar and cuff, sling and swathe, or a commercially available shoulder immobilizer are equally effective. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Immobilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Posterior dislocation &ndash; A posterior shoulder dislocation causes prominence of the posterior shoulder with flattening anteriorly. The coracoid process appears prominent. The patient holds the arm in adduction and internal rotation and is unable to externally rotate (",
"      <a class=\"graphic graphic_picture graphicRef73358 \" href=\"UTD.htm?43/9/44178\">",
"       picture 3",
"      </a>",
"      ). Posterior shoulder dislocations are commonly associated with tuberosity and surgical neck fractures. Radiographic evidence of this dislocation on a standard anteroposterior view is subtle and often missed. Clues to the diagnosis include the \"light bulb\" sign, rim sign, and trough line sign (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61746 \" href=\"UTD.htm?33/39/34431\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54093 \" href=\"UTD.htm?16/38/16994\">",
"       image 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Posterior shoulder dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inferior dislocation &ndash; Patients with inferior shoulder dislocation hold the involved arm above their head and are unable to adduct the arm. Approximately 60 percent of patients have some neurologic dysfunction, with the axillary nerve most commonly involved. Neurologic dysfunction usually resolves spontaneously following reduction. Rotator cuff tears or greater tuberosity fractures are present in 80 percent of cases. Arterial injury occurs in approximately 3 percent of patients. Radiographs reveal the humeral head beneath the coracoid or the glenoid (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70882 \" href=\"UTD.htm?39/17/40223\">",
"       image 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inferior shoulder dislocation (luxatio erecta)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Simon RR, Sherman SC, Koenigsknecht SJ. Emergency Orthopedics: The Extremities, 5th, McGraw-Hill, New York 2006.",
"    </li>",
"    <li>",
"     Schaider J, Simon RR. Shoulder injuries. In: Clinical Practice of Emergency Medicine, Wolfson AB, Hendey GW, Hendry PL, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.1033.",
"    </li>",
"    <li>",
"     Sineff SS, Reichman EF. Shoulder joint dislocation reduction. In: Emergency Medicine Procedures, Reichman EF, Simon RR (Eds), McGraw-Hill, New York 2004. p.593.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/4\">",
"      Simonet WT, Melton LJ 3rd, Cofield RH, Ilstrup DM. Incidence of anterior shoulder dislocation in Olmsted County, Minnesota. Clin Orthop Relat Res 1984; :186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/5\">",
"      Zacchilli MA, Owens BD. Epidemiology of shoulder dislocations presenting to emergency departments in the United States. J Bone Joint Surg Am 2010; 92:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/6\">",
"      Brady WJ, Knuth CJ, Pirrallo RG. Bilateral inferior glenohumeral dislocation: luxatio erecta, an unusual presentation of a rare disorder. J Emerg Med 1995; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/7\">",
"      Riebel GD, McCabe JB. Anterior shoulder dislocation: a review of reduction techniques. Am J Emerg Med 1991; 9:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/8\">",
"      Stayner LR, Cummings J, Andersen J, Jobe CM. Shoulder dislocations in patients older than 40 years of age. Orthop Clin North Am 2000; 31:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/9\">",
"      Visser CP, Coene LN, Brand R, Tavy DL. The incidence of nerve injury in anterior dislocation of the shoulder and its influence on functional recovery. A prospective clinical and EMG study. J Bone Joint Surg Br 1999; 81:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/10\">",
"      Wen DY. Current concepts in the treatment of anterior shoulder dislocations. Am J Emerg Med 1999; 17:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/11\">",
"      Cleeman E, Flatow EL. Shoulder dislocations in the young patient. Orthop Clin North Am 2000; 31:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/12\">",
"      Perron AD, Ingerski MS, Brady WJ, et al. Acute complications associated with shoulder dislocation at an academic Emergency Department. J Emerg Med 2003; 24:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/13\">",
"      Chong M, Karataglis D, Learmonth D. Survey of the management of acute traumatic first-time anterior shoulder dislocation among trauma clinicians in the UK. Ann R Coll Surg Engl 2006; 88:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/14\">",
"      Emond M, Le Sage N, Lavoie A, Rochette L. Clinical factors predicting fractures associated with an anterior shoulder dislocation. Acad Emerg Med 2004; 11:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/15\">",
"      Shuster M, Abu-Laban RB, Boyd J. Prereduction radiographs in clinically evident anterior shoulder dislocation. Am J Emerg Med 1999; 17:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/16\">",
"      Hendey GW, Chally MK, Stewart VB. Selective radiography in 100 patients with suspected shoulder dislocation. J Emerg Med 2006; 31:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/17\">",
"      Hendey GW. Necessity of radiographs in the emergency department management of shoulder dislocations. Ann Emerg Med 2000; 36:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/18\">",
"      Blake R, Hoffman J. Emergency department evaluation and treatment of the shoulder and humerus. Emerg Med Clin North Am 1999; 17:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/19\">",
"      Barber FA, Ryu RK, Tauro JC. Should first time anterior shoulder dislocations be surgically stabilized? Arthroscopy 2003; 19:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/20\">",
"      Gleeson AP. Anterior glenohumeral dislocations: what to do and how to do it. J Accid Emerg Med 1998; 15:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/21\">",
"      Perron AD, Jones RL. Posterior shoulder dislocation: avoiding a missed diagnosis. Am J Emerg Med 2000; 18:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/22\">",
"      Tan AH. Missed posterior fracture-dislocation of the humeral head following an electrocution injury to the arm. Singapore Med J 2005; 46:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/23\">",
"      Hashmi FR, Pugh M, Bryan S. Simultaneous bilateral posterior dislocation of shoulder. Am J Emerg Med 2002; 20:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/24\">",
"      Cicak N. Posterior dislocation of the shoulder. J Bone Joint Surg Br 2004; 86:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/25\">",
"      Gor DM. The trough line sign. Radiology 2002; 224:485.",
"     </a>",
"    </li>",
"    <li>",
"     Harris JH, Harris WH. The Radiology of Emergency Medicine, 4th, Lippincott Williams &amp; Wilkins, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/27\">",
"      Cisternino SJ, Rogers LF, Stufflebam BC, Kruglik GD. The trough line: a radiographic sign of posterior shoulder dislocation. AJR Am J Roentgenol 1978; 130:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/28\">",
"      Saupe N, White LM, Bleakney R, et al. Acute traumatic posterior shoulder dislocation: MR findings. Radiology 2008; 248:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/29\">",
"      Aparicio G, Calvo E, Bonilla L, et al. Neglected traumatic posterior dislocations of the shoulder: controversies on indications for treatment and new CT scan findings. J Orthop Sci 2000; 5:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/30\">",
"      Yamamoto T, Yoshiya S, Kurosaka M, et al. Luxatio erecta (inferior dislocation of the shoulder): a report of 5 cases and a review of the literature. Am J Orthop (Belle Mead NJ) 2003; 32:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/31\">",
"      Grate I Jr. Luxatio erecta: a rarely seen, but often missed shoulder dislocation. Am J Emerg Med 2000; 18:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/32\">",
"      Ameh V, Crane S. Nerve injury following shoulder dislocation: the emergency physician's perspective. Eur J Emerg Med 2006; 13:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/33\">",
"      Mallon WJ, Bassett FH 3rd, Goldner RD. Luxatio erecta: the inferior glenohumeral dislocation. J Orthop Trauma 1990; 4:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/34\">",
"      O'Connor DR, Schwarze D, Fragomen AT, Perdomo M. Painless reduction of acute anterior shoulder dislocations without anesthesia. Orthopedics 2006; 29:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/35\">",
"      Burton JH, Bock AJ, Strout TD, Marcolini EG. Etomidate and midazolam for reduction of anterior shoulder dislocation: a randomized, controlled trial. Ann Emerg Med 2002; 40:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/36\">",
"      Taylor DM, O'Brien D, Ritchie P, et al. Propofol versus midazolam/fentanyl for reduction of anterior shoulder dislocation. Acad Emerg Med 2005; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/37\">",
"      Miller SL, Cleeman E, Auerbach J, Flatow EL. Comparison of intra-articular lidocaine and intravenous sedation for reduction of shoulder dislocations: a randomized, prospective study. J Bone Joint Surg Am 2002; 84-A:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/38\">",
"      Matthews DE, Roberts T. Intraarticular lidocaine versus intravenous analgesic for reduction of acute anterior shoulder dislocations. A prospective randomized study. Am J Sports Med 1995; 23:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/39\">",
"      Orlinsky M, Shon S, Chiang C, et al. Comparative study of intra-articular lidocaine and intravenous meperidine/diazepam for shoulder dislocations. J Emerg Med 2002; 22:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/40\">",
"      Fitch RW, Kuhn JE. Intraarticular lidocaine versus intravenous procedural sedation with narcotics and benzodiazepines for reduction of the dislocated shoulder: a systematic review. Acad Emerg Med 2008; 15:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/41\">",
"      Dhinakharan SR, Ghosh A. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Intra-articular lidocaine for acute anterior shoulder dislocation reduction. Emerg Med J 2002; 19:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/42\">",
"      Kosnik J, Shamsa F, Raphael E, et al. Anesthetic methods for reduction of acute shoulder dislocations: a prospective randomized study comparing intraarticular lidocaine with intravenous analgesia and sedation. Am J Emerg Med 1999; 17:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/43\">",
"      Naredo E, Cabero F, Beneyto P, et al. A randomized comparative study of short term response to blind injection versus sonographic-guided injection of local corticosteroids in patients with painful shoulder. J Rheumatol 2004; 31:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/44\">",
"      Sethi PM, Kingston S, Elattrache N. Accuracy of anterior intra-articular injection of the glenohumeral joint. Arthroscopy 2005; 21:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/45\">",
"      Wakai A, O'Sullivan R, McCabe A. Intra-articular lignocaine versus intravenous analgesia with or without sedation for manual reduction of acute anterior shoulder dislocation in adults. Cochrane Database Syst Rev 2011; :CD004919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/46\">",
"      Kuhn JE. Treating the initial anterior shoulder dislocation--an evidence-based medicine approach. Sports Med Arthrosc 2006; 14:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/47\">",
"      Bishop JY, Flatow EL. Pediatric shoulder trauma. Clin Orthop Relat Res 2005; :41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/48\">",
"      Baykal B, Sener S, Turkan H. Scapular manipulation technique for reduction of traumatic anterior shoulder dislocations: experiences of an academic emergency department. Emerg Med J 2005; 22:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/49\">",
"      Anderson D, Zvirbulis R, Ciullo J. Scapular manipulation for reduction of anterior shoulder dislocations. Clin Orthop Relat Res 1982; :181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/50\">",
"      McNamara RM. Reduction of anterior shoulder dislocations by scapular manipulation. Ann Emerg Med 1993; 22:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/51\">",
"      Kothari RU, Dronen SC. Prospective evaluation of the scapular manipulation technique in reducing anterior shoulder dislocations. Ann Emerg Med 1992; 21:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/52\">",
"      Schubert H. Reducing anterior shoulder dislocation. Easy is good. Can Fam Physician 2002; 48:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/53\">",
"      Sagarin MJ. Best of both (BOB) maneuver for rapid reduction of anterior shoulder dislocation. J Emerg Med 2005; 29:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/54\">",
"      Leidelmeyer, R. Reduced! A Shoulder, Subtly and Painlessly. Emergency Medicine 1977; 9:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/55\">",
"      Simon RR. The Hennepin technique. Ann Emerg Med 1984; 13:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/56\">",
"      Eachempati KK, Dua A, Malhotra R, et al. The external rotation method for reduction of acute anterior dislocations and fracture-dislocations of the shoulder. J Bone Joint Surg Am 2004; 86-A:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/57\">",
"      Plummer D, Clinton J. The external rotation method for reduction of acute anterior shoulder dislocation. Emerg Med Clin North Am 1989; 7:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/58\">",
"      Mirick MJ, Clinton JE, Ruiz E. External rotation method of shoulder dislocation reduction. JACEP 1979; 8:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/59\">",
"      Ufberg JW, Vilke GM, Chan TC, Harrigan RA. Anterior shoulder dislocations: beyond traction-countertraction. J Emerg Med 2004; 27:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/60\">",
"      Mattick A, Wyatt JP. From Hippocrates to the Eskimo--a history of techniques used to reduce anterior dislocation of the shoulder. J R Coll Surg Edinb 2000; 45:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/61\">",
"      Milch, H. Treatment of Dislocation of the Shoulder. Surgery 1938; 3:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/62\">",
"      Russell JA, Holmes EM 3rd, Keller DJ, Vargas JH 3rd. Reduction of acute anterior shoulder dislocations using the Milch technique: a study of ski injuries. J Trauma 1981; 21:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/63\">",
"      Johnson G, Hulse W, McGowan A. The Milch technique for reduction of anterior shoulder dislocations in an accident and emergency department. Arch Emerg Med 1992; 9:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/64\">",
"      Garnavos C. Technical note: modifications and improvements of the Milch technique for the reduction of anterior dislocation of the shoulder without premedication. J Trauma 1992; 32:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/65\">",
"      Yuen MC, Tung WK. The use of the Spaso technique in a patient with bilateral dislocations of shoulder. Am J Emerg Med 2001; 19:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/66\">",
"      Yuen MC, Yap PG, Chan YT, Tung WK. An easy method to reduce anterior shoulder dislocation: the Spaso technique. Emerg Med J 2001; 18:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/67\">",
"      Maity A, Roy DS, Mondal BC. A prospective randomised clinical trial comparing FARES method with the Eachempati external rotation method for reduction of acute anterior dislocation of shoulder. Injury 2012; 43:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/68\">",
"      Cunningham N. A new drug free technique for reducing anterior shoulder dislocations. Emerg Med (Fremantle) 2003; 15:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/69\">",
"      Zahiri CA, Zahiri H, Tehrany F. Anterior shoulder dislocation reduction technique--revisited. Orthopedics 1997; 20:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/70\">",
"      Noordeen MH, Bacarese-Hamilton IH, Belham GJ, Kirwan EO. Anterior dislocation of the shoulder: a simple method of reduction. Injury 1992; 23:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/71\">",
"      Poulsen SR. Reduction of acute shoulder dislocations using the Eskimo technique: a study of 23 consecutive cases. J Trauma 1988; 28:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/72\">",
"      . Injuries of the shoulder. Dislocations. Clin Orthop Relat Res 1989; :4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/73\">",
"      Chitgopkar SD, Khan M. Painless reduction of anterior shoulder dislocation by Kocher's method. Injury 2005; 36:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/74\">",
"      Freundlich BD. Luxatio erecta. J Trauma 1983; 23:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/75\">",
"      Yanturali S, Aksay E, Holliman CJ, et al. Luxatio erecta: clinical presentation and management in the emergency department. J Emerg Med 2005; 29:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/76\">",
"      Guha AR, Jago ER. Irreducible acute anterior shoulder dislocation. Int J Clin Pract 2004; 58:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/77\">",
"      Harvey RA, Trabulsy ME, Roe L. Are postreduction anteroposterior and scapular Y views useful in anterior shoulder dislocations? Am J Emerg Med 1992; 10:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/78\">",
"      Tannebaum RD, Kondabala RK, Stockmal PJ. Postreduction radiographs for anterior shoulder dislocation: a reappraisal. Ann Emerg Med 2001; 37:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/79\">",
"      Hendey GW, Kinlaw K. Clinically significant abnormalities in postreduction radiographs after anterior shoulder dislocation. Ann Emerg Med 1996; 28:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/80\">",
"      Steinmann SP, Moran EA. Axillary nerve injury: diagnosis and treatment. J Am Acad Orthop Surg 2001; 9:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/81\">",
"      Saab M. Brachial plexus lesion following an anterior dislocation of the shoulder. Eur J Emerg Med 2004; 11:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/82\">",
"      Shears E, Sunderamoorthy D, Ali SA. Brachial plexus injury after anterior shoulder dislocation: a case report. Acta Orthop Belg 2005; 71:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/83\">",
"      Maweja S, Sakalihasan N, Van Damme H, Limet R. Axillary artery injury secondary to anterior shoulder dislocation: report of two cases. Acta Chir Belg 2002; 102:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/84\">",
"      Kelley SP, Hinsche AF, Hossain JF. Axillary artery transection following anterior shoulder dislocation: classical presentation and current concepts. Injury 2004; 35:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/85\">",
"      Onyeka W. Anterior shoulder dislocation: an unusual complication. Emerg Med J 2002; 19:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/86\">",
"      Beeson MS. Complications of shoulder dislocation. Am J Emerg Med 1999; 17:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/87\">",
"      Griffith JF, Antonio GE, Yung PS, et al. Prevalence, pattern, and spectrum of glenoid bone loss in anterior shoulder dislocation: CT analysis of 218 patients. AJR Am J Roentgenol 2008; 190:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/88\">",
"      Pollock RG, Bigliani LU. Glenohumeral Instability: Evaluation and Treatment. J Am Acad Orthop Surg 1993; 1:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/89\">",
"      Chalidis B, Sachinis N, Dimitriou C, et al. Has the management of shoulder dislocation changed over time? Int Orthop 2007; 31:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/90\">",
"      te Slaa RL, Wijffels MP, Brand R, Marti RK. The prognosis following acute primary glenohumeral dislocation. J Bone Joint Surg Br 2004; 86:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/91\">",
"      Dollery W. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Immobilisation after first anterior shoulder dislocation. J Accid Emerg Med 1998; 15:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/92\">",
"      De Baere T, Delloye C. First-time traumatic anterior dislocation of the shoulder in young adults: the position of the arm during immobilisation revisited. Acta Orthop Belg 2005; 71:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/93\">",
"      Smith TO. Immobilisation following traumatic anterior glenohumeral joint dislocation: a literature review. Injury 2006; 37:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/94\">",
"      Funk L, Smith M. Best evidence topic report. How to immobilise after shoulder dislocation? Emerg Med J 2005; 22:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/95\">",
"      McNeil NJ. Postreduction management of first-time traumatic anterior shoulder dislocations. Ann Emerg Med 2009; 53:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/96\">",
"      Itoi E, Hatakeyama Y, Sato T, et al. Immobilization in external rotation after shoulder dislocation reduces the risk of recurrence. A randomized controlled trial. J Bone Joint Surg Am 2007; 89:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/97\">",
"      Miller BS, Sonnabend DH, Hatrick C, et al. Should acute anterior dislocations of the shoulder be immobilized in external rotation? A cadaveric study. J Shoulder Elbow Surg 2004; 13:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/98\">",
"      Murrell GA. Treatment of shoulder dislocation: is a sling appropriate? Med J Aust 2003; 179:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/99\">",
"      Itoi E, Hatakeyama Y, Kido T, et al. A new method of immobilization after traumatic anterior dislocation of the shoulder: a preliminary study. J Shoulder Elbow Surg 2003; 12:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/100\">",
"      Finestone A, Milgrom C, Radeva-Petrova DR, et al. Bracing in external rotation for traumatic anterior dislocation of the shoulder. J Bone Joint Surg Br 2009; 91:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/101\">",
"      Liavaag S, Brox JI, Pripp AH, et al. Immobilization in external rotation after primary shoulder dislocation did not reduce the risk of recurrence: a randomized controlled trial. J Bone Joint Surg Am 2011; 93:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/102\">",
"      Milano G, Grasso A, Russo A, et al. Analysis of risk factors for glenoid bone defect in anterior shoulder instability. Am J Sports Med 2011; 39:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/103\">",
"      Bushnell BD, Creighton RA, Herring MM. Bony instability of the shoulder. Arthroscopy 2008; 24:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/104\">",
"      Kirkley A, Werstine R, Ratjek A, Griffin S. Prospective randomized clinical trial comparing the effectiveness of immediate arthroscopic stabilization versus immobilization and rehabilitation in first traumatic anterior dislocations of the shoulder: long-term evaluation. Arthroscopy 2005; 21:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/105\">",
"      Davy AR, Drew SJ. Management of shoulder dislocation--are we doing enough to reduce the risk of recurrence? Injury 2002; 33:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/106\">",
"      Bottoni CR, Wilckens JH, DeBerardino TM, et al. A prospective, randomized evaluation of arthroscopic stabilization versus nonoperative treatment in patients with acute, traumatic, first-time shoulder dislocations. Am J Sports Med 2002; 30:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/107\">",
"      Handoll HH, Almaiyah MA, Rangan A. Surgical versus non-surgical treatment for acute anterior shoulder dislocation. Cochrane Database Syst Rev 2004; :CD004325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/108\">",
"      Kralinger FS, Golser K, Wischatta R, et al. Predicting recurrence after primary anterior shoulder dislocation. Am J Sports Med 2002; 30:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/109\">",
"      Provencher MT, Frank RM, Leclere LE, et al. The Hill-Sachs lesion: diagnosis, classification, and management. J Am Acad Orthop Surg 2012; 20:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/110\">",
"      Burkhead WZ Jr, Rockwood CA Jr. Treatment of instability of the shoulder with an exercise program. J Bone Joint Surg Am 1992; 74:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/8/10378/abstract/111\">",
"      Aronen JG, Regan K. Decreasing the incidence of recurrence of first time anterior shoulder dislocations with rehabilitation. Am J Sports Med 1984; 12:283.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 258 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10378=[""].join("\n");
var outline_f10_8_10378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anterior shoulder dislocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mechanism of injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Radiographic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Associated injuries (Hill-Sachs and Bankart)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Posterior shoulder dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inferior shoulder dislocation (luxatio erecta)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      REDUCTION PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anterior shoulder dislocation reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Suggested approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Reduction techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Posterior shoulder dislocation reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Inferior shoulder dislocation reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Operative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/258\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/258|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/13/30943\" title=\"diagnostic image 1\">",
"      Anterior shoulder dislocation radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/13/31967\" title=\"diagnostic image 2\">",
"      Anterior shoulder dislocation scapular Y view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/39/34431\" title=\"diagnostic image 3\">",
"      Posterior shoulder dislocation and fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/9/42142\" title=\"diagnostic image 4\">",
"      Hill Sachs lesion AP radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/44/8911\" title=\"diagnostic image 5\">",
"      Bankart lesion AP radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/56/10113\" title=\"diagnostic image 6\">",
"      Anterior shoulder dislocation with greater tuberosity fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/38/16994\" title=\"diagnostic image 7\">",
"      Posterior shoulder dislocation radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/17/40223\" title=\"diagnostic image 8\">",
"      Inferior shoulder dislocation radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/6/18531\" title=\"diagnostic image 9\">",
"      Shoulder fracture dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/258|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/28/15814\" title=\"figure 1A\">",
"      Basic shoulder anatomy anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/60/28613\" title=\"figure 1B\">",
"      Basic shoulder anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/6/27748\" title=\"figure 1C\">",
"      Basic shoulder anatomy posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/21/21843\" title=\"figure 2\">",
"      Positions of anterior dislocations of the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/258|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/17/273\" title=\"picture 1\">",
"      Anterior shoulder dislocation appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/30/26080\" title=\"picture 2\">",
"      Shoulder axillary view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/9/44178\" title=\"picture 3\">",
"      Posterior shoulder dislocation appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/0/6147\" title=\"picture 4\">",
"      Scapular manipulation for shoulder reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/42/37537\" title=\"picture 5\">",
"      External rotation for shoulder reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/55/7026\" title=\"picture 6\">",
"      Milch technique for shoulder reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/25/44434\" title=\"picture 7\">",
"      Stimson technique for shoulder reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/50/28451\" title=\"picture 8\">",
"      Traction-countertraction for shoulder reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/47/29427\" title=\"picture 9\">",
"      Spaso technique for shoulder reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/30/35298\" title=\"picture 10\">",
"      Posterior shoulder dislocation reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/34/21028\" title=\"picture 11\">",
"      Inferior shoulder dislocation reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/258|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?13/20/13632\" title=\"movie 1\">",
"      Posterior shoulder dislocation with blocked external rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?23/45/24272\" title=\"movie 2\">",
"      Upright BOB technique for shoulder reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?24/22/24928\" title=\"movie 3\">",
"      External rotation technique for shoulder reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?0/33/530\" title=\"movie 4\">",
"      Traction-countertraction with axillary pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?0/12/196\" title=\"movie 5\">",
"      Fares technique for shoulder reduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10663?source=related_link\">",
"      Acromioclavicular joint injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33912?source=related_link\">",
"      Frozen shoulder (adhesive capsulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=related_link\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41592?source=related_link\">",
"      Multidirectional instability of the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=related_link\">",
"      Presentation and diagnosis of rotator cuff tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=related_link\">",
"      Shoulder impingement syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_8_10379="Performance Arozullah index";
var content_f10_8_10379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Performance of the Arozullah respiratory failure index",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Point total",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent respiratory failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &le;10",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        11 to 19",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        20 to 27",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        28 to 40",
"       </td>",
"       <td>",
"        10.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &gt;40",
"       </td>",
"       <td>",
"        26.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Arozullah, AM, Daley, J, Henderson, WG, Khuri, SF, Ann Surg 2000; 232:242.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10379=[""].join("\n");
var outline_f10_8_10379=null;
var title_f10_8_10380="Fontaine stages and Rutherford categories PAD";
var content_f10_8_10380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fontaine stages and Rutherford categories PAD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Fontaine",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Rutherford",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle2\">",
"        Clinical",
"       </td>",
"       <td class=\"subtitle2\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle2\">",
"        Category",
"       </td>",
"       <td class=\"subtitle2\">",
"        Clinical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td colspan=\"1\">",
"        Asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        Mild claudication",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td colspan=\"1\">",
"        Mild claudication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        IIb",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Moderate to severe",
"claudication",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td colspan=\"1\">",
"        Moderate claudication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Severe",
"claudication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Ischemic rest pain",
"       </td>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td colspan=\"1\">",
"        Ischemic rest pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        IV",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Ulceration or gangrene",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td colspan=\"1\">",
"        Minor tissue loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Major tissue loss",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000; 31:S1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10380=[""].join("\n");
var outline_f10_8_10380=null;
var title_f10_8_10381="Classification DILI";
var content_f10_8_10381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74021%7EGAST%2F72121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74021%7EGAST%2F72121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifications of drug-induced liver injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Clinical laboratory",
"       </td>",
"       <td>",
"        Hepatocellular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed hepatocellular/cholestatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Mechanism of hepatotoxicity",
"       </td>",
"       <td>",
"        Direct hepatotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Idiosyncratic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immune-mediated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Histologic findings",
"       </td>",
"       <td>",
"        Cellular necrosis or apoptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phospholipidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinuoidal obstruction syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spectrum of drug-induced hepatotoxicity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Subclinical",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfonamides, salicylates, sulfonylureas",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Acute hepatic injury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytotoxic (acetaminophen)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Steatosis (amiodarone; AZT, ddI)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cholestatic (bactrim, rifampin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Extrahepatic (penicillin, sulfa)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Chronic cholestasis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Intrahepatic cholestasis (bactrim)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Biliary sclerosis (floxuridine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Granulomatous disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amiodarone, sulfonamides, isoniazid",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Chronic hepatic injury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chronic active hepatitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Steatosis (steroids, MTX, EtOH)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phospholipidosis (amiodarone)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fibrosis/cirrhosis (AZA, OCPs)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Vascular disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hepatic vein thrombosis (OCPs)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          SOS (herbs, OCPs, chemoTx)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Peliosis hepatis (AZA, OCPs)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Neoplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Adenoma (OCPs)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          HCC (aflatoxin, alcohol)",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MTX: methotrexate; AZA: azathioprine; OCP: oral contraceptives pills; chemoTx: chemotherapy; SOS: sinusoidal obstruction syndrome (veno-occlusive disease); HCC: hepatocellular carcinoma.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10381=[""].join("\n");
var outline_f10_8_10381=null;
var title_f10_8_10382="Pleural pressure volume curves";
var content_f10_8_10382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Pleural pressure volume curves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 416px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The solid circles represent a normal pressure/volume (P/V) curve of a patient with a hepatic hydrothorax, and a calculated Pel of 3 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O/L. The open circles represent the P/V curve of an entrapped lung associated with malignancy. The elastance during the first 1250 mL is normal. After 1250 mL fluid is removed, the slope of the curve becomes very steep and has a calculated elastance of 22 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O/L. The pressure/volume curve depicted by the solid triangles is from a patient with a trapped lung. The initial mean pleural liquid pressure is negative, and there is a steep slope throughout the entire thoracentesis. The calculated elastance is 216 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O/L.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American College of Chest Physicians. Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: technique and clinical implications. Chest 2004; 126:1764. Copyright &copy; 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10382=[""].join("\n");
var outline_f10_8_10382=null;
var title_f10_8_10383="Plantar grasp";
var content_f10_8_10383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Infant plantar grasp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 411px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGbAf0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACijNIWoAWjNRl/emNJSuBNmk3VXMtMMtLmHYt7qNwqn51NM1LnCxd3ijeKzjP7037TjvRzBY1Awpc1mLdc9asR3ANVcRcoqNXBqQHNMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiig0AFITTGcCozJSbAezVC8tDtkVVkbms5SKSJWlqMuTUZNJUXHYeWNN3UlFK4xc01jxS0xqAI3aoGcipXqCSmIYZTmporgjHNU360gbBppgb9vcZ71ejkziuct5cGtOCbI5NWpCaNaimxNujU+op1aEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUjDKkZpaKAM2SfBIPBHWmpLk9aj1ZDFMrj7r8H6//q/lVaGTmsZblo0s5FROppY3yKkOCKQFUjFFTMtREYqbDEooooGFMan0xqBELVA/Sp3qB6Yis/Wo+9SPTBgZJpgSxdauwtisr7Qf4FyPU1Ytp5WlRcBi3YDn/OcUgsdRYnNqh+v86sVHbJ5UCIeqjB+tSVutiGFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAhuoVuIGjboR19D61zvzI7K4wynBFdRWZq1oXHnxj5lHzD1FROPUaZUhkq0j561mRtz7Vbjbisii1kGo360gakJoYCUUUUigpjUhlB4QFz/s9Pz6VG/mEfwr+tITQyQ1A5pZBJn76/8AfP8A9eoXZgOVB+hqgGPVefJIUdCefpU24NnHUdqaRk0CCJK3dCtFy1yw5Pyp/U1jxjmun0og6fDjsuPxHFXFXYnsW6KKK1JCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKD0oooAw9TtPIbzYx+6Y8j+6f8KgiauiZQykMAQeCDWDe2ptJflyYWPyn0PpWU421KTJVOaWoY245NKAZjk5Efb1b/AOtWZSFaTJIjG4jqew/Ggxbv9a2726CpQuBwMCkosO4mMDApj9KkqN6QmVJKgc1YkHNVpKoRE6huvX19KZkqfn5X19PrTzSrQBLHW3oknySRHqDuH0P/ANcfrWEn7th/cP6H/CtKwcx3UTDudp+h/wDr4pxdmDRv0UDpRW5AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHPGs0TRuMqwwakoNAHLrkymJv4Dh/f2rSiGao3GUv5weu8k/j0/Sr1ucrXPY0JGXiomFWDyKgcc0MQymMOKfTW6Uhsqyjmqsgq3KKqyUxEJoFBpVoAmUA8HoauaWhkuY0POw7j9B0/XH61VjFa2ij95P/ur/wCzU4q7Doao6UUUVuQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGDrCbNQDdnUH8R/kVJatxUmup8sMnoxX8x/9aq9q3SsZaMtF/tUUgqRelNekwIKRqU0lSMgkFVJBVmWaIEgyJn0zz+VVZJVz0kP/AGzb/Ci4EJFKo5prSLnpJ/37b/ClSWPcBvUH0JwaYWLMda+j/fm+i/1rLQVp6Of304/2VP8A6FVR3E9jUooorYgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKerIHsZP9nDfkayLZq37hBLBJGejqV/MVzNu52qTwSOaynuUjWRuKSRwq5Y4FVvN2qABuc9Bn/PFc9qeukyNDp5EkvRp8cL7KP61m5WNIxctjYv9QjtV3TOIgei4y7fQdqxJ9XlnYiCDK+sx3f8AjvSqVvas7b5SXc9S3JNaMcIUcCsnJs3VNRK7S38ow1wyL6Jhf5VA9tI3+slkb6sTWntxTWAqWWrGTJalRlWYH2NV/Ou4GBWaQoDypbII/GtsoD1qpPCD0o1Q9HuWrO6OwSQtlO4UYI+q9Pywa6LQLgSXTjjLRgkA+h6j2+auIEbxSb4iVb1FbXh/VIrW8V7wMnysu9RkHJB5HXtWsJq5hOk0tNTu6KrWt7bXQzbzxyeytzVnIrrTucuwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABFcrc4t7m4U/wAMh4+vIH6iuqrlfEm6G+kde8RlHuwGP8KzqbFR3Oe1rUpJJHsrZsE8TOv/AKCKbYWioo4rN0pDuJkyXzznrmuigACjFcd7s7uVRVkORABTwKUCnBaZIxhTSKmK00igCIimMM1K1Rt1oKRA6A1E0QqyelNxU2KuUzBzkHBHQirVvqOpW3+qu5CB2c7h+tO2g0bBTV1sJ2e5ft/FN5HxcW8Uo9VJU/1rTtvFFtJgTQzRH1wGH6c/pXPCIelVr9mR4oIMLLJkluu1RWsaku5k6UXsjuX1nT0g86S7iRM4+Y4P5daik8QaakCyrcrKGOAsYLNn6dR+NccukblE5uZGkUfxYIH4VTu7uHyw7KIr2I4yBj8fcH0rT2rBYaL0uei6bqtnqKt9kmDMv3kIKsv1B5q9mvJL/UlWOK9tpGiuNvWNtpPqMiuj0fVZrHUbeCW4ee2uCFIkcsyMehBPP4VUaqejJnhWldHcUUUVqcoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVk6/ZNdQK6AsyZBUdSp64/IH8K1qKTV1Yadjy3yjBfSK2Mk7uP88c54rUgPFaPja1CNbXir3MbkD8R/Wsq1YECuGceWVjug+aCZeUcU4CkToKU0yRDTDTjTT1oGMamEVIaYaQ0MbrTafim4oKEFKKMUYoAr3159kiUhN8jttRM4yfr6VEmnvPN9ou5SHfChU4CjsM9fftWdrs5TVLZQCdkZf8zj+lPXWQFwTVI1jTbV0GpXKablrYFdnUZ++O+feubuJxql488jmKADCrnG7/AOtVjUrwXdwkKcvIwVR9eK6GLQLa20wW5jWXcfmZhyccf0/WjcuTVOyOOEVsJP3dw42nIUtlc/SrsOrXiXUUsjQsInDjaepBzV06DHHMFWBHDHHzZB/MGqv9l2zSSIYnidDg7HJ/nmlexXNFns2h6pBq+nx3VsTtbhlPVW7g1oV5Z4U1KbQzMkY8+GTBKucEEdwR/h2rsbTxTayYFxDND7gbx+nP6V0xqprU8upQlFvl2Oioqra6ha3f/HvcRyHuoPI+o61aBzWt7mDVtwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimNIA23vQA+ikBpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAp6vZrf6fNbscFx8p9GHIP5159aOyOUcYdTgj0Ir02uE8U2otda8xRhJ13/APAhwf6fnXPXj9o6cPLVxJYW3CntxVa1bOKnc81iatDk5NNfrxREeaSTqaQDTTSKdRQMYaTFOIpjSBe9AwIpMUbwelKDQMwtWiI1y2kP3Xj2fiCT/Wrdx4einYFI0jLfeYE/yFP1mAzWpKcOvzKfQ1Y0bUDc2q7yu9flOexq4mik7aGXqOiQaXBHLaR5dHDsx6sQc1qfb0liPklGDfMuWx15rTkhE6YlwV9K5nWNGuLctLYfMvUx/wBRTemxDtLcfYan9qvfIKIsyklQWHXpWvJpkQhJHzSMcs3qa8a8V3t1pl3DqVvuSSNh5ikYww6Ej0PSu+0DxZFqVhBcow2uORn7p7g0m9Lhyu9kby6eF5xUotsL0og1WCUD5hV2O5iYDBGKSsS+ZGdJbr/EOnTIp8eqXtiP3VzKV6BGO8H2Gen4VoSNEy9qzpogXkl42xocfWne2wt9y/a+Jr0PtnEEjdSACMfjW1Ya/b3EixygwyNwMnKk/WuKt4WjXe/3n+b8KrXLlbV2JPJOPpTVWSE6EZaI9Tnnigj3zOsadMscCmw3dvP/AKmaOT/dYGvNLe5uZbWINM7BB8qudwFJ9r2v++jK/wC0ORV+38jP6t5nqYOaK89tNQnRQba7kC+z5H5HitKHXb9OC8cn++nP6EVarIh0JI7CiuZTxJKB+8tFb3WTH9KcfFCL9+0k/wCAsD/hVe0j3I9jPsdJRWbp+tWd8QscmyU/8s5OG/8Ar/hWlVJp7ENNOzCiiimIKKKKACiiigAooooAKKKCcUAFIWABJ4A71Tu9Rhgyo/eSf3V7fU9qx57ia5b963y9kHT/AOvUuaQ0jSudSUtstjn1ft+FMgmPckk9SaoxxnPSrcSYrPmZVjQjkyKnDVRQ4qVZKtSJsW6KYjZp9WIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuX8cx/6PaTd1kK/mP8A61dRXPeN/wDkFRf9dh/I1nV+BmlH40c5ZtyKvP0FZdu+0itMHcgxXIjsluCcNSyetNPSk35PNAhwpDRQaABvu1mXW4ng1pSH5azZmyxFJlwIopipwatxyZqiwqxCeBQi2i594EHoawJHOlaiZCM20hw49Pet2LkcVU1O2E0JBGeKshbmxbODErxOGjYZGeanaVSCDjNcZoF7Jp10bOU7oH/1YPb2rppGjfkA8+lXcfKZPiTQLDWbOeC5jH7xSu5RyM968N8LC68P+Lbvw7eyhSz4jLD5S2MqR/vLj9K+g327ThifrXj/AMctHdLS28QWSstzaMqSuvUJn5W/Bv501rowkre8uhvFrq2P7yIkeqH/ABrRsNRLtiOTLD+E8H8q4WL4jW11o2krAEl1q+dbfyO0blgpdvbuB3rt44oodRtrpoldY5FZkYZDDPIIPtWbhY1upK8dTbg1E9H61diu1kieNjw3XNdDqPhKxvIhLp7fZ3YblwSUP4dvw/KuQvtPu9Mn8u6jIz91hyG+hpyg47nPGpCptuaf2qJgNxGAMHms+8/0qRUjGF9Paq6rG7ZYc+ta+nrCvIxmp3LvyjrezKRAe1QzWx54rdiKEY4oe2VxTsZ8+pycls0b7oiUb1FPivZ4eJU3j1HBremshzxVSWy9qVuxopp7kMF/DLgbsH0PFWSEccYrPmshg8VXaNoV4Z1x6Eile24+W+xoTW3deD7Vq6V4huLQrFehpohwGH3lH9a5N7y4TIWUke9NS6lk4ZyDVRlbVEzhdWkeuWt1DdwiW3kDoe47fX0qavKtO1S50+cSQS8ngqeQw967jSPEVtfKEkIhn/useD9DXTCopbnHUpOO2xu0VGJBRvFaGJJRTN9G4UAPoqC5uI7aFpZWwg/X2FYNzqtxPkIrxRnsvX8/8KmUkhpXNq6v4bfKs26T+4vJ/H0rJur6e4+UHy4/RTyfqapRFScDr6Hg1ajjzWbk2VaxHHH6DirMUNSJHirCLgVIDEjAqTGKXpTGamAhbFAbmmE5pAcUrjL0D1aU8VmxNg1eibIrWLIZLRRRViCiiigAooooAKKKKACiiigAooooAKKKKACsDxqpOlRn0mGfyNb9ZXieLzdFuMdVw/5GoqK8WXTdpo4dOoq/bvxg1UhXIFTx/KcVxI7pFpvu1CGqdeRUDDY3PemSiRDkU8CoY2w2DVvbkZFAPQgcZFUZo8P04rTZahlj3DpzTsNMzMKTwc5pyj0qvcpNaHeBvQZ49AavwqsiJIvKsARRYvmJbdeM0+RMg0+NcCnH0qjNs5nWbHepZOGHII7H1q3oWo/bLcwy4F1HwR6+9aNzEHU8VyeqQTWV4t1bHa6H8/Y0k7Gi946cXUbOyHAkXqO9eV/FLwdrWo288/h/WdRZWB83TZbpjG47hMn/AMdPH06V6A0sWr2i3Vodl0g+Ze+fSq9veedlJDiQcEYwarmcTRQVRWZ8x+ALOWP4h6Va3cTxTRXGXRxgqVUnkH6V9Jsu5SKzNW8L2V74h0/Wgvl39ox+dR/rFKkbW+meDW5HETniic+Z3KoU/ZJpno/g26+1eHrXccvEDE34dP0xWtcW8VzE0c8ayI3VWGRXJ/Dt2EV9CfuqyuPqcg/+giuxrpi7xPKqrlm0jiNX8KyxFpdNPmR9fKY/MPoe/wDP61zMjzWsrJKjIy9VYYIr12qWpaZa6jHsuog3ow4ZfoazlRW8TWGIa0lqeeWmpr0ZsGtm1vFfG1s1meIfDcmmZmQmW1J++Byn1/xrIiaaE7kY4FYax0Z0csZq8TulYOvNNeNTVDSLozxDd1rS7VSMGrMrvbqewqjeWihCcVqmqN8SRgUmi4ydzlrqALIcVVH3sHg1szREtk1Rlt8vmoSsdDldFXnNSBiPrUotz3pHgNMnQuWOu31mQElLoP4H+Yf/AFq6Ky8UwS4FzG0R/vL8w/xrjTEw7U5QR2q1NozlTiz0q2v4LgfuJkf2B5/KrSS15cCcg9/WtC31K+jXal1Lj3Of51oqvcydHszp/E11sMKFgoA3bj2z/wDqP51x9/fPICltkDu/ep5zLcvvnleRvVjmovJAPSs5Suyo0ktyvZajf2hAZvPi/uSc/keorq9L1SK5ACbg/eJvvD6HuP1rn1iB6io5YjGQyEhhyCOoqU7FSgpHfROrLlTmpQa5PSNb3yLDdMEn6K5+6/sff3ro4phIPQjgj0NaKVzmlFx3J2amE5pM5ooEFITQTio2agCVXwavW75rJDc1etX5FXElmmOlFNQ8U6tiQooooAKKKKACiiigAooooAKKKKACiiigAqG8hFxaywnpIhQ/iMVNRQB5zbKR8rDDLwR6Gp5Btwat6zb/AGbWJgBhJf3i/j1/XNQsu5K4bWdjvb5kmETZANFyu6MkdRUELYcqetXEG4EdaBMz4H3oD3BINbFq6NGBWHdxyW0rPEMqeq/1p1veoxADbX/ung0h2ujbmUDpUBFV1uC2MmpQ/HWqQrWGXMAkiIx2rN05jBcG1kOFPKE/qK20dSMZFUNVs/NTfHw45BFMLlrbiiq+nXXnxFJMCZOGHr71ZIoEMYZFZepWokQgitXFMmj3IaTKTseeSNPpF758GdufnX+8K0p5YLxUu7fAY/eFXtRsxIWBFczc6Zd20jPZysgPVeo/Klfozqi+qN62uEcAFhmtEbAhPFcOsmqRnlYmPqV/wr1jwBpUL6NbajdRlrtyx+Y5VcMQCB+HvVU1zOyJrVeSN2bHhTTmsdP3SrtmmO9lP8I7D/Pc1t5rEu9bUSvBZqJHQlWkb7qnuPcj8PrVYXV1Jy1y/wBFAAH6Zro54x0R5rjKT5mdJmjNc59ouR0uZR+R/mKa11c97qX/AMdH8hS9qheyZ0FzElxBJFKN0bqVYeoNeZmEQSyQydUYoSfY4rpnlkfIaef/AL+MP5GoFhiViwRdx5JxyaznLmNqScLlfR4TGjNggduOtai1EpAp+7ipG9RW6VUuSMc1NJMqjkis66uUI4IoY4op3L81ReTmpLmUE9aou/NQzoii2knPNTLhqzkfBq1FJxQKSLXlK1NNsO1Kj81LvpkFf7PSrFg1Y3ZpeKdguMVe1KVp2aQnigQ3pUUvNOc81GTSKKF3DuBxWv4f1lnkW2ujiccRuf4x/dPvVKRc1n3MJzuXII5BHalsDipKzPSYpBImR+NPJrmvD2rG5j2TH/SIx8/+2v8Ae+tb5kBXINaJ3OOUXF2YrNUTvTHeoWeqJJd3NXLR/mFZgfmrlo3zCnHcGb8RyKkqGA/KKmrdEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBg+LIAbWK4GAYm2k+zcfzxWJEcrVz4lSumhRIhILzrn8AT/MCsfRrkXNvFJ3I5+veuWrpI66SvAkvFMWJQDx1xRa3QST5uQa1JYleIqRwRXN3Mb2zkEEx54I7VmzWFnozdn2TpkYrMuLFXHQUy2nOzKsCp9DVpJx3oQ2rbFWBHiOCzEeh5qbzsH0qypjkBBA5qhdwzRHdF+8j9D1H40yfUnW5APWrMdyrjBNYImV2IB2uOqng0omdDSuPlNC9iZHFxbnDr+vtVmyvEuo8jhxwynsazEvSRhqqSkxyia3ba/wCh+tFx8p04+8KdMQsZrJ07U0nO1/kkHVT/ADHtUmpXyRxH5qTZPK7lO7lRZOTyajJjYYOKxnuGnnL8+wq1EskrKiBmc9FUZJ/Cpvc3Ssiw9tG5wo3MeAB1J7CvS4IxpOghQBi2gJOO5Ayf1rnPC3h6dLlLy/QoqHMcbdS3Ykdsfz+ldLr3Gh6h/wBe8n/oJrqpRcU2zjr1FOSijktLhMdnHk5Y43H1Nab4jjzVG0YC3iqa7kygANYJmkldkxkBphaqLTY7037R71VxcpdJpC2O9UvtHvS/aBjrRcfKWGmwaY91tXrzVdpFYdaYQmRuNK5VkV7maWT7ucVUmEgXJra3whAMCqd3PBtIGKTLi/I5ya4KnBNRrPk0zUcNcZj5Wq8eS3FSjbRmgJPerEUo9aoKpIqeJCKZLRpJJnFTq+apRDjmp1baKZkyyrU9TmqwapVamSTilPSow3FKTxTENeoGNSO1RMakpBnmopADmnE1G7UFFF5JLS4SeA7XQ5FdhpWopeWqSx8K2QV/ut3H9a5G5wwNM8PXptNT+zu2Ipzgf7L9j/SiLsyKkOaNzvHeoyaYr7lBozWxxDgeav2Q+YVnoOa1LBeRVITNu3+5U1Rwj5akrZEhRRRQAUUUUAFFFFABRRmjNABRRmjNABRRRQAUUUUAc14/t/O0Ldj/AFUqt+fH9a4jQ5xazNDIcI5ypP8Ae9K9P1q2+16Xcwd3Q4+vUfrXmaWy3EJGK56q1OzDu8Wjohc/LioZyHQ5XcR2Fc7b3MmnyeVcs7Q5wrddn/1q2YpdyhlIZG5BByDWJq42KkyW4beC0be4K/8A66gMw/gkVh7GtkRxzDDgVlX+gRSZeMYb1FAJka3ZU1Zi1DsxrAuLC7tv9XKWA7NzVX7dNCcTxEj1Wpuactzq5kt7pfnUE+o4Iqk9tcQ/6phMn91+o/GqFnfJLjyn59D1rSiuuPmouTy2KbyoP9YDE3o4x+vSgP6EEVZup4pEIcA1H4d0N9W1FfIEkdqjAyyKcAD0HbJoSbdkDfKrsqXEXAYZUjkEHBFQWlrqWrXa2tuTM3qRjaPUnoBXox8F2jON11clP7vy8/jit7TdNtdNgMVnCsak5OOrH1J71tGg76mMsSkvdMjTvB+l2saebEbiUAbmkY4J7/L0rdgtoLdcQQxxDphFC/yqaiuhRS2RyOUpbsKjuYknt5IZBlJFKMPYjBqSiqJOAZZbB/s12pV1JAbGA49RTJJhjrxXe3FvDcRmOeJJEPZhkVkzeGdPkPyiWP2SQ4/XNYOk+h0qun8Rxkkp5xVV53HStvxJo9tYRpHay3DXMmSu5lwoHc8Vgpo9+wz5/wCaisZRadjeMk1cY1zIKYbqTPWrH9j3o6yofwpP7Lul6mM/8BpWZfMiFbuTPWrcNwZODQmny9wn5GrsNgE69aLEuSGGNmTg1ny2MrOeTiuhjhAAFTrCoHSqsTztHJSacVXkVB9kC9q6u8QY4FY86ipsXGTZneVjtSKp9KucYqMgZosVcauacM0oIFJvAPFAiRM1KjYqvvo8zFAi2HFI0vHFVfMz3p680XFYkLZprGlAApjGgaEJqGRqc74qnNLjvSKQkz1k3rlJVdThlOQaszzZNZ90S5AAyT0FJlJHplq++NW/vAN+YqeobVNsaL/dRR+lWVWuhbHmvcdEuTWzp8fI4qtYWMkw3AbU/vN3+lblvAsKYXn3NaRRLJFGBS0UVoSFFFFABRRRQAU18kcHFOpDQBnz224nJJz6mqMtgh6qp/AVsSVSuJAoNIpGU9oqHhVH0FNM0sP3J5Vx/tkj8qlkkeVtsKlz/Klj0p5fmuHP+6p/rQMg/ty5iIBkV/Zl6/lirtr4hD8XFtIvunI/XFBtILdfkRR+FUXR7iQpEMKOrUBoa39v2YYBxKgPcqP6GrI1axIyLhMfjWBLDHaoTjLdyetQRWctwd8wKx9l9frRcVkdBJrVswP2bM2O44X8/wDCuCkuUg1i5jKBIi+VHYZ5xXS3LRWluScAAcVy11DcXN4Zlt3KMOwzWdTVG9BpSLd7ax3EZIwciuYke60qUm1bMZOTG3Kn/A1umN4eMvGfQ8D9arXKCVSGwTWL8zrSuWNI1aG/XCHy5x96Njz9R6itqKfIw1ee3tm0cgkhJV15BBwRWzpXiBWCw6kRHKOBL/C319D+lS0S4nUT26SL0rn9Rs0BO4VtxSblBVsqeQRyDVPUFDDmoY4PU5l9NDPuQlWHQjjFT2yXjTx2yJ57yMFXHBqtqetW9mWSEiaYcYU8A+5q78NdYc+KGe+lUJJCy88Beh4/KnGPMx1JWTaOp0jwVLNJ5mrSeXH2ijbJP1Pb8K7m0tobSBILaNY4kGFVRgCmQXlvM22KZGb0zzVmuyMFHY86c5T3CiiirICiiigAooooAKKKKAOM11w+vTbz/q1VQPwz/WlRxsH0pnipDBrRk/hmjBH1HB/pVUSjYOe1ckviZ2xV4oul1NRsy5qi8+Khe696m5SiaJdR6Unmrmsh7r3qBrts0rlqBviZaiku2zhRWJ/aDIOVzSLqy5+ZDRzDVM1pHcgk9KoTN60fb4pE4OKyr28LPtjpXGo2LDygHANRvMMVSXexzk07BNBVkTedk04N3quo29KkHNAiUyGkDE0wCnjAoESL71OrcVW3AUgloFYub+Khlk96iMlSWlndahIY7OFpWzgkcBfqe1G4basqTTehqBIprknyUZ8cEgcD6mu+0fwdbxYk1I/aJevlgkRj+rfjx7V1CWsKReUkUax9NgUAflWqot7mUsQlpE8rs/DpfD3UoA/upz+tbNlpdtbj9zEqjvIeT+frXaHSbTPEOPoxH9asQ2VvF9yFAfUjJ/M1apWMJVXLdmBaWM0/3E4Y5LHgD/PtW1aaXDDtaT9649RwPwq+BinVooJGLYAUUUVYgooooAKKKKACiiigApDS0hoArT5xxVRrUyHMh49BWiwqFqQ0RIiRLhFA+lMlmCillOBmqUm6RuPzoGRSs00m1e9WsJbQ/ShFSBCT+dU8S30oC5WLP3vWgBbWE305lkH7pDwPU1duSkaE9hUwVLeEIgAUCsDVblp5Ps8Z+994jsKAKMm/Ubvj/VIePc+tblnY4QDHFN0yzVEAA4FbUMYUUA2UjYIy4YAj0NZl94ctpgdqmNvVOP06V0uKawFDSYKTWx5rqXh27hBaErOo/h+61cpdW4ZmV1KuOCCMEV7bNErDkVzmuaFa33zSoVkHSROD/wDXrKVPsdEK7+0eWQzX2nk/Y7h4wf4eo/I8Vas7fXfELtGsztEOGb7ij8hz9K6OHwsDeBZ7hmgJwMLg/jXf6XpsFlapFBGERR0FTGlfcudaK+E8ju/AuowRlo2glI/hViD+oqtoFlc2WsxrcwSRNgj5lx29a9nvIl29Kx7i3Uj5gCPQir9mk7oy9u2rMoRSYUEZ4rqdH1EXCiKY/vQOCf4x/jWALKIDIQD/AHeP5VCuYJgpJ2nlT3BqzLc7qisjSL9pG8mZtzY+Rj1Psa16ogKKKKACiiigAooooAytf0oanbqEYJNGcox6e4NctNpGoW6sZLYsijJdXUjH4nP6V31c942uGi0pYlyBNIEb6YJ/pWc4r4janOWkUcS11E4yDJj/AK5sf6VEZk9X/wC/bf4Vs6aY3QgqKu+RCeqrXNY6b2OX8yPuW/79t/hSrsbpv/74b/CunEEH90U7yIewFFh85zqWwk6EH2qYaVvH3a3DBGOmKa0ypwMUWFzPoc/Nokn8DYFVjpgi69a6GS8AyKzbmfeTS0LTkZrxBQBULLVqQ5NQnrSLRCE9adtx0p1BIAoAZ061E8mOlE0vpVcbnPHSkNEgZi2KsQxPJIscaM8jcKijJP4Vq6B4dudR2yEGG3/56MPvf7o7/Xp9a73SdItdNjIto/nb70jcs31Pp7dK1hTctTCpWUdjmtJ8JM+yTUm2r18lDz/wJv8AD866+1toreJY4I1jjXoqjAFWAuKftrojBR2OSVRy3GqvFPApcUtWZjcUuKWigAFFFFABRRRQAUUUUAFFFFABRRRQAUGig0AMaomFTGo2FAyB1BHIqtIVT2q2/AzWXcbp5fKTj1PoKQxgD3s20ZEIPzH19q1ERYkCqMU2CJYYwqjgCmzPgGgClql0sETMT+HrWZpsJY735dzk1HfMbq+CZykfJ+v/AOr+dalpHtAoGaFsoVRirSnioIuBUgNAh5amlqaTTTQArNxVG6kQKQWGauEZqidLjeUszvgnOM0AUrOMz3q7R8oO4muhHAxUcEEcKbY1Cj+dPNCEQ3I+WqEiblNXr1/Lgdz0UE1m6dI80LGQ5bdj9BQNEeCE6VRuU3fXtWtImFrPnXBNAEFvKVYclWByD6Gut0+5F1bh+jDhh6GuNmyuGFbPh24/ftHnh14+o/8ArE/lQDOiooopkhRRRQAUUUUAFYHjO2efSg8YJMLhyPbBB/nW/SMAwweRSkrqw4y5Xc8qgmaInHSri3hI5rsLnw1p07lhG8RPJ8tsD8ulUn8I25/1dzMv+8Af8K5/ZSR1+2gznvtmB1pjX+Otbr+En/gu1I94yP61UuPCF4R+7mgb6kj+lS4T7FqpT7mYdSUD71V31GNm+9U9z4T1RAdsIcf7LisS90TUrfJe1nUDvsOKzakt0bQdN9TVa6iYDDAms28ulRuDzWMxnRsHcD6UjLI/UHmoubcqRqrcBjnNPMmelUbeJieQatBGxgCqRm7DWc5prscVOlq7etaem6Dc3zgRJ8vdzwo/Gmk3sQ5pbmHHA80iqqszMcAAZJPsK7jw34VWHZcaioaTqsPUL7t6n26fWtvQ9Bt9MTcAJLg8GQjp7D0FbCrXRClbVnLUr82iGomKkC04ClxW5zXAClxRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBDTCKkNNIoAqXJwvFMtoRGCT948mrDLls4oxxQMjc1m6lMIomJ6AVoydDWDrBLBY/7zfpSGivpkZYGRvvMcmtqFelU7KPagrRhFAyZBTwKFFPGKBCbaTaKduppYUCDApeKYWpN1Ax5OBTN3NNJpE60AV9XOLKT3GPz4qppo2x4qxrJ/0XHqw/nUdkPlFALYmmHFZtwOtasw+Ws2470AUHGQQaNCkKahED/DIB+fy/1pzDmoLQbNTGOu9G/Uf4UDO8ooopkBRRRQAUUUUAFFFFABRRRQAUUUUAFGKKKAIJ7S3uBieCKT/fQH+dZc/hrS5WybVF/3CR/Ktuik4p7opSa2Zz48K6YOkcn/AH2alh8OabEci33H/aYn+tbeKMUuSPYftJdyhFptnERstYVI77BVsIB06VJiimkkS22NApcUtFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIRS0UAMIppFSEUhFAFWYcVjXa77sL/AHFz+Z/+tW661RliBkJxzSZSZDEmFFW4h0qPZipk6UASigtTc00mgALUhNJmkoAXNJmiigAoTrRSrQBU1cZts+jL/OmWf3RU+pc2xHckfzqG24AoAnmPy1mTnmtGY/LWbLyTQBXYc1FaJu1eMepT/wBCqztyan02HOqwt2AJP4CgDp6KKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUhpaKAGEVCY+TVnFIRQBUZOaQLirJWmlKQ7kBppFTlKYVoGRYpKkK0hWgBlQXl1FaRb5SeTtVVGWduwA7mrOKypFEniSNZP+WVsXiB7lmwx/AAD/AIFQBLBqUUkUrSrJbtCR5iTABlz0PBIwfUH+VEeqWuE82VImeVolWQgFmDFcD6kVia3MbjUbq005Vubia0KSAOAsRRsgseefn6Dnp0HNYepWU+rrZy4SNnuJNgjcsEaWDejE4HIcfrQB2T6laXdmlxDLmElvmKkdBk59OOajm1C3tLm3gmcrJPu2cccDnJ7Vzf2uXThYRmOdVcw3Miop4j8nY5PsrAEj3qk121zb6aJUuXuoZj56vC5cQFw4kxjpgKPxI7GgDs7HUYdSs/Pt94TcVw64Pr09wQfoaYRkmuEVpxHZhY7ovBeq+1YJM+UqxqJsbemEIx/tGt7TJp7G+vrm+huhaX0nmw4gd2TA24ZVBK5ABGR7daAOgSPJ6VpaXBiZ5COi7Qf8/Sq1gftECS+XLGGzhZV2tjPcdvxrZgXZEBigTJKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKADFJilooAaRSFafRQBEVppSp8UmKAIClVb3T7W9CreW0U4U5USIGx9M1o7aTaKB3MxNPiilt2gRYkhVkWNFAXDY7Dp90VOkCooVFVVHQAYxVzYKNtAXKckW7ApPJ4q7so20CKPk0ohq5spdgoAhjjqwBgUAYooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plantar reflex is well established by 32 weeks conceptional age and disappears by three months of age. During the normal plantar grasp, the toes plantar flex around the examiner's finger when it is brought across the ball of the foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_8_10383=[""].join("\n");
var outline_f10_8_10383=null;
